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ABSTRACT
Cancer is a leading cause of death worldwide, accounting for at least 10% of all deaths
globally. Current therapies for cancer include surgical excision, chemotherapy and
immunotherapy. CD8* T cells are adaptive immune cells responsible for eradicating tumor cells.
However, these T cells can be rendered ineffective through tolerance. Yet in various mouse
models and human patients, tolerant T cells persist. The aim of this project is to identify factors
that support T cell persistence in a tolerizing tumor environment. Using a spontaneous prostate
cancer model, we study antigen-specific T cells that have been shown to be locally tolerant in the
prostate tumor environment. In this thesis, I compare the immune response in normal, antigen-
bearing, tumor transgenic and tumor-antigen transgenic mouse models. Results show that T cell
infiltration and persistence in the tolerizing prostate environment is dependent on the presence of
antigen and tumorigenic/tumor-related factors. Although antigen-specific T cells are locally
tolerant in the prostate of tumor-antigen transgenic mice, they generally persist in the prostates of
tumor transgenic mice regardless of whether antigen is present or not. Further analyses revealed
that T cells infiltrate the prostate and can proliferate extensively in the tolerizing tumor
environment due to the presence of antigen. Interestingly, antigen-specific T cells are depleted
from the spleens of mice that express antigen in their prostates. This depletion from the spleen is
correlated with low levels of IL-7Rc expression and the presence of antigen in the
prostate. Tumorigenic or tumor-related factors in the prostate also appear to be supporting CD8'
T cell persistence. This thesis shows that persistence of antigen-specific T cells in the tumor
environment is not dependent on IL-15 and IL-7; cytokines known to support proliferation and
maintenance of persisting functional CD8' T cells. Some potential candidates are also discussed.
More investigative work needs to be done to identify the role of these factors on T cell
infiltration and persistence. In combination with tolerance-breaking strategies, persisting T cells
may be excellent vehicles for delivering site-specific cancer immunotherapy.
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Title: Cottrell Professor of Immunology and Biology
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CHAPTER 1
INTRODUCTION
1.1. Background & Significance
Cancer is a leading cause of death worldwide, accounting for at least 10% of all deaths
globally 1. Almost twenty-five percent of the 2.4 million deaths in the United States (U.S.) are
due to cancer 2, 3. About 1.5 million new cases are expected to be diagnosed in 2009 2. The
current therapies for cancer include surgical excision of the affected tissue, chemotherapy,
radiation therapy, hormone therapy and immunotherapy 4-6. Immunotherapeutic regimens so far
have involved transfer of dendritic cells (DC) 6-8 and/or CD8' T cells 9~11, depletion of T
regulatory cells 12, and administration of cytokines that enhance T cell survival such as IL-2 and
IL-15 9-11, 13-16. Refractory cases, particularly when the diagnosis is made in the late stages of
cancer, are often fatal. Even with the armamentarium of current treatment options, when cancers
from all sites are combined, a patient's 5-year survival is estimated at about only 66% 2. Thus,
developing new treatment strategies and optimizing current therapies is essential in the fight
against cancer.
One of the difficulties of current immunotherapy for cancer is the development of
tolerance 1. CD8+ T cells are the main adaptive immune cell type responsible for destroying
tumor cells 18, 19, as well as cells infected with intracellular pathogens such as viruses 20. NaYve
CD8* T cells recognize antigen (a peptide sequence foreign to the host), and are activated to
eliminate the cells that bear this antigen. Tumor cells have tumor antigens that can be processed
and presented by professional antigen-presenting cells such as DC to CD8' T cells. Then,
activated CD8' T cells eliminate tumor cells. However, the host's CD8* T cells may not be
completely effective in combating tumor cells, and cancer develops. Adoptively transferred
CD8' T cells targeting specific tumor antigens also develop this problem. Different mechanisms
have been proposed to explain why CD8* T cells become ineffective against tumor cells 6, 21-23
In some cases, tumor cells down-regulate molecules like major histocompatibility complex
(MHC) class I that would allow them to be recognized by CD84 T cells 22. They may also up-
regulate Fas ligand and other molecules to induce apoptosis in CD8* T cells 21-25. Sometimes,
secretion of cytokines such as interleukin (IL)-4, IL- 10, and transforming growth factor-p (TGF-
D) by the tumor cells, or other cell types in the tumor environment, suppress cytolytic function of
CD8* T cells 21-23,26,27. Host CD8' T cells may also just be "ignorant" of the presence of tumor
cells 18, 23. This state in which host or adoptively transferred CD8' T cells used in
immunotherapy are unable to perform their effector functions despite antigen stimulation is
called tolerance.
Tolerant (non-functional) T cells have been identified in animal models for cancer, as
well as human patients, but no one has reported how or why tolerant T cells persist in the tumor
environment. In addition to identifying the mechanisms for tolerance, published research have
focused mainly on characterizing the phenotype of tolerant T cells and developing strategies to
restore T cell function. In most cancer models available, non-functional T cells are depleted
from the host 28-30. Such models do not mimic the phenomenon of tolerant but persisting T cells
observed in certain cancers, and their use is limited to studies that develop strategies for
enhancing survival and maintenance of cytolytic T cells. In other studies where tolerant CD8* T
cells are generated, the cells are characterized as having impaired proliferative ability, defective
T cell receptor (TCR) signaling, and increased sensitivity to cell death 28,31,32. For example, in a
study by Dubois et al. (1998), F5 CD8' T cells became tolerant after continued exposure to
cognate influenza virus NP 366-374 peptide. The peptide antigen was delivered via multiple
intraperitoneal injections 28, instead of being constitutively expressed in the mice like our tumor
model. The tolerant T cells displayed the hallmarks described above. Antigen-specific T cells
with impaired proliferation, IL-2 secretion, and Calcium ion release in response to peptide
stimulation, have also been reported to persist in the TCRxgag mice which have the tumor
antigen expressed in the liver 3. Most of these experiments, however, evaluate cell proliferation
and cytolytic activity in vitro and may not accurately reflect tolerant T cell response in the
tolerizing environment in vivo.
In the cases where tolerant T cells are maintained, the reports focus on how to reverse the
cells to a functional state 8, 11,33 Some of these efforts have resulted in only a transient break in
T cell tolerance 8. Overwijk et al. (2003) performed studies with B 16 transplant melanoma
mouse model. Without exogenous administration of IL-2, tumor-specific CD8+ T cells were
maintained in the solid transplant tumor for up to 30 days but were not fully activated ".
Boosting with peptide vaccination and IL-2 on day 30 increased the number of tumor-specific
CD8' T cells by 34-fold and increased interferon (IFN)-y production, suggesting reversal of the
transferred T cells into functional state ". Anderson et al. (2007) showed that tumor Ag-specific
CD8+ T cells adoptively transferred into TRAMP mice failed to degranulate and secrete IFN-y
and granzyme B 8. Again, this group focused on how to restore the effector function of these
cells by using ex vivo-matured DC vaccinations. Although they observed increased proliferation
and IFN-y production initially, despite DC vaccination, the tumor-specific T cells in the TRAMP
prostate became tolerant by week 5 8. These studies alert us to the fact that in order to develop
effective immunotherapy against cancer, it is imperative that we understand the mechanism for
persistence of T cells in a tolerizing or immunosuppressive environment. Recently, Thomas et
al. (2009) showed that mice with MC57-SIY-Lo brain tumors developed recurring brain tumors
even though 2C T cells persist for up to 35 days in this tissue 3. After the initial tumor
regression, the MC57-SIY-Lo mice developed tumor cell variants that did not express the SlY
peptide and presumably could no longer be recognized by the persisting 2C T cells 3. The
authors do not expound on the phenotype of these persisting 2C T cells or the mechanism by
which they persist.
1.2. Description of the TRAMP-SlY Experimental System
Our model system is based on the transgenic adenocarcinoma of the mouse prostate
(TRAMP) model developed by the Greenberg lab in the 1990s and resembles prostate cancer
progression in humans 34, 35. In this mouse model, the prostate-specific rat probasin promoter
drives expression of the oncoprotein simian virus 40 (SV40) large tumor T antigen-coding region
in the prostate epithelium 35. This oncoprotein inhibits the regulatory function of the p53 and
retinoblastoma (Rb) tumor suppressor genes 3. After puberty, the male mice develop
intraepithelial hyperplasia within 2-4 months of age 35. Then, the disease progresses to neoplasia
by 4 months of age, and invasive (metastatic) adenocarcinoma is evident from as early as 5
months old 35. Ultimately, the mice develop fatal androgen-independent prostate cancer as is
seen in humans 34
In the Chen laboratory, former postdoctoral fellow, Dr. Ailin Bai, created a T cell
antigen-specific model by modifying the TRAMP model such that its prostate epithelial cells
express the SIYRYYGL (SIY) peptide. This model is called the TRAMP-SIY model. Dr. Bai
engineered a D-galactosidase-SIY (P-gal-SIY) fusion protein under the control of the prostate-
specific promoter such that the prostate epithelial cells in mice of C57BL/6 background express
SlY peptide (B6-SIY). TRAMP mice and B6-SIY mice were crossed to create double transgenic
TRAMP-SIY mice. To date, both the TRAMP and TRAMP-SIY mice models show similar
disease progression.
Antigen-specific immune response to cells expressing SlY peptide is studied using the 2C
TCR system. 2C TCR cells recognize SIY-Kb complexes presented on target cells 36. In our lab,
2C T cells are isolated from transgenic mice on a recombination activating gene-i deficient
background (2C RAG 1), and are adoptively transferred into recipient mice by retroorbital
injection. A monoclonal antibody 1B2 specific for the 2C TCR makes it possible for us to
identify and track these T cells in different tissues. In addition, our group also has congenic 2C
Thyl.l+ RAGlV transgenic mice that allow us to detect 2C TCR CD8' T lymphocytes using a
Thyl.1 antibody, particularly in cases where one may not want to perturb the TCR-MHC
interaction.
In vivo activation of 2C T cells is achieved by vaccinating recipient mice with the
Influenza A/WSN-SIY influenza virus. This virus, developed in collaboration with Dr. Astrid
Flandorfer (Mount Sinai School of Medicine), is a mouse-specific recombinant HINi strain
where the SLY peptide has been engineered onto the neuraminidase stalk. NaYve 2C T cells are
adoptively transferred into mice post-puberty that also receive low dose WSN-SIY virus
infection intranasally. Antigen-presenting cells presenting the SlY peptide to T cells having the
2C TCR eventually lead to activation of 2C T cells in the mediastinal lymph nodes (draining
lymph nodes of the lung, the site of infection). These activated 2C T cells exit the lymph nodes,
infiltrating different peripheral tissues including the prostate (Fig. 1).
This combination of the TRAMP/TRAMP-SLY prostate cancer models, the 2C TCR
system, and the WSN-SIY engineered virus constitute our experimental system. Our studies
show that 2C T cells that infiltrate the prostate of the TRAMP-SIY mice rapidly lose their ability
to secrete IFN-y, TNF-ca and lyse tumor cells 37. These 2C T cells exhibit the phenotype of
exhausted effector T cells; they express high levels of PD-1 (Fig. 2). This immunosuppression
occurs locally in the prostate 37; 2C T cells from other tissues, for example, the lungs of
TRAMP-SIY mice are able to secrete IFN-y upon antigen stimulation. 2C T cells from the
TRAMP prostate retain more functionality 37. These results confirm that we have developed a
prostate cancer model that mirrors the disease progression observed in humans 4 3 and allows
us to track CD8' T cell response to a specific antigen at the tumor tissue site. In addition, this
model is unique because it allows us to study local immunosuppression in the prostate; a
phenomenon that has also been observed in human patients with esophageal squamous cancer 31
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Figure 1. Tolerant antigen-specific T cells persist in the tumor environment but are
depleted from other tissues.
Prostates, lungs, spleens and prostate draining lymph nodes (PDLN) from TRAMP-SlY (solid
diamond) and TRAMP (open diamond) mice were harvested nine days, one-, two-, and five-
months after 2C T cell transfer and WSN-SIY influenza infection as described in the methods
section. Cells were stained with 1B2 and CD8ca antibodies, as well as DAPI or PI to exclude
dead cells, followed by flow cytometry analysis. After gating on live lB2* CD8' cells, total cell
numbers were calculated by multiplying the ratio of lB2* CD8' cells from FlowJo analysis and
the total cell numbers counted by hemacytometer and tryphan blue exclusion before antibody
staining. The plot shown is generated using Microsoft Excel. Each shape represents one mouse.
Solid black bars indicate the average of the data for each mouse model (n;>4 per group). The p-
values for cell numbers from student t-tests comparing TRAMP to TRAMP-SLY are given for
p0.05.
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Figure 2. Tolerant 2C T cells express higher levels of PD-1.
Tissues from TRAMP (red) and TRAMP-SIY (blue) mice were harvested 45 dpi and stained
with Biotinylated 1B2, Streptavidin-APC, CD8a-FITC, and PD-1-PE (clone J43) antibodies, as
well as PI for analysis by flow cytometry. FlowJo software was used to generate PD-i
expression histograms.
1.3. Persistence of Tolerant T Cells in TRAMP-SlY Prostate
By analyzing the number of 2C T cells using the flow cytometry technique, we observe
that tolerant 2C T cells persist in both TRAMP and TRAMP-SIY prostates for at least five
months post-transfer and infection (mpi) (Fig. 1). Initially there is a marked increase in the
number of 2C T cells in TRAMP-SIY prostate until 1 mpi. Then long-term, there is a population
of 2C T cells that are maintained in TRAMP-SIY prostate (Fig. 1) although these cells are
tolerant. We define this population of T cells that are maintained in the tissues as persisting T
cells. The mice analyzed in these studies are between the ages of 4 - 8 months old that have not
developed visible palpable masses. As time goes by, the number of T cells again increases in the
prostate tumor environment of 5 mpi recipient mice i.e. mice that are approximately 8 months
old at the time of analysis (Fig. 1).
Interestingly, antigen-specific 2C T cells are preferentially depleted from other tissues of
TRAMP-SIY mice over the course of time. For instance at 2 mpi, 2C T cell numbers in
TRAMP-SIY spleens (Fig. 1) and prostate draining lymph nodes (PDLN, Fig. 1), are lower than
that of TRAMP. In the lungs, both TRAMP and TRAMP-SIY mice show declining numbers of
2C T cells (Fig. 1). This data suggests that tolerant antigen-specific T cells persist in the
tolerizing TRAMP-SIY prostate, but antigen-specific T cells are depleted from other tissues.
1.4. Summary of Thesis
This thesis reveals that the presence of persistent antigen and tumorigenic/tumor-related
factors contribute to persistence of tolerant antigen-specific T cells by inducing proliferation. By
comparing the CD8' T cell response in normal, antigen-bearing, tumor transgenic, and mouse
models having both the tumor and antigen transgenes, this report shows that antigen-specific T
cells generally persist in the prostates of tumor transgenic mice regardless of whether antigen is
present or not. This persistence occurs even though antigen-specific T cells in the tumor
transgenic TRAMP and TRAMP-SIY prostates are functionally different. Interestingly, the
presence of antigen in the prostate leads to depletion of antigen-specific T cells from other
peripheral tissues such as the spleen. This depletion correlates with low levels of IL-
7Ra (CD127) expression. Previous reports classically characterize tolerant T cells as having
defective TCR signaling, impaired proliferation and increased sensitivity to cell death 28, 31, 32
Our data shows that T cells persist in vivo by proliferating extensively in the tolerizing tumor
environment. These results are in contrast to in vitro studies concluding that tolerant CD8* T
cells are characterized by impaired proliferation. Furthermore, in addition to antigen, it appears
that tolerant T cells in vivo depend on tumor-related factors in the tolerizing environment for
their persistence. These studies show that these tumor-related factors do not include IL-15 and
IL-7 cytokines known to support functional memory T cell maintenance. This revelation about a
dominant role for tumor-related factors opens up new areas of investigation to identify molecules
that support T cell infiltration and persistence. This knowledge used in combination with
tolerance-breaking methods might provide novel strategies in the treatment of cancer.
Understanding the molecular mechanisms for persistence of tolerant T cells may also prove
beneficial by providing new ways to induce T cell suppression, for example, in organ
transplantation and treatment of autoimmune diseases.
1.5. Materials and Methods
Mice & Viruses: 2C TCR transgenic mice on RAG1/~ and B6 backgrounds were maintained at
the Massachusetts Institute of Technology (MIT) Animal Care Facility. Congenic 2C TCR
Thy 1.1 mice were also bred in our facility. Recipient mouse strains (TRAMP and TRAMP-SIY)
ages 3-8 months old, were also maintained in the MIT facility. Recombinant WSN (HiNi)
influenza virus with SIYRYYGL peptide engineered onto the neuraminidase stalk originally
constructed by plasmid-based reverse genetics 38 was grown on Madine-Darby Canine Kidney
(MDCK) cells.
Antibodies & Reagents: Biotinylated 1B2 monoclonal antibody was produced in-house. 1B2 is
a monoclonal antibody specific for the 2C TCR. Other anti-mouse monoclonal antibodies,
CD16/32 (Fc blocker), Streptavidin-APC, CD8a-PerCP-Cy5.5 clone 53-6.7, CD8ca-APC,
CD8a-PE, CD8a-FITC, CD90.l(Thyl.1)-APC, CD90.l(Thyl.1)-FITC, and PD-I-PE clone J43
for flow cytometry studies were purchased from BioLegend (San Diego, CA), BD Biosciences
(San Jose, CA) or eBioscience (San Diego, CA). Pierce Chemical 4',6-diamidino-2-
phenylindole hydrochloride (DAPI) P146190 was purchased from VWR (USA). Propidium
iodide P4170 (PI) was purchased from Sigma-Aldrich (USA).
Lymphocyte Isolation (Lymph Nodes and Spleen): Lymph nodes (LN) and spleens from 2C
RAGl-'~ mice were extracted, one mouse at a time, after carbon dioxide (C0 2) inhalation. The
sacrificed animal's fur was sterilized with 70% ethanol. Dissected LN and spleens were stored
on ice in 4 ml of RPMI 1640 media supplemented with 5% fetal bovine serum and 10 mM
HEPES buffer solution (RPMI complete). After dissection, the LN were gently mashed between
rough surfaces of two microscope slides immersed in RPMI complete to release lymphocytes.
Cell suspensions were filtered through an 80-ptm nylon mesh (Sefar) and transferred into 15-ml
BD Falcon tubes kept on ice. A similar procedure was followed for cell isolation from the spleen.
Splenocytes used for flow cytometry analysis were further purified by a red blood cell (RBC)
lysis step after grinding.
Cell Transfer & Influenza Infection: Cells isolated from 2C lymph nodes and spleens as
described above were resuspended in Hank's Balanced Salt Solution (HBSS, serum-free media),
filtered and kept on ice. Following approved animal care facility protocol, recipient mice were
anesthetized with 2.5% Avertin and intranasally infected with 100 pfu of WSN-SIY or 100 pfu
WSN-SIIN Influenza virus suspended in 50 p1. Still under anesthesia, infected mice were
immediately injected retroorbitally with 1-2 x 106 total live cells suspended in 100 pl HBSS.
Lymphocyte Extraction (Prostate and Lungs): Prostate lobes were extracted by microdissection
following procedures in Current Protocols in Immunology 3. Briefly, the urogenital system from
each mouse was extracted after CO2 inhalation, and transferred into 15-ml of RPMI complete on
ice. A dissecting microscope was used to identify prostate lobes in the urogenital system placed
on cold 1x PBS. The prostate lobes were subsequently removed using tweezers and transferred
into 2-ml of 1 mg/ml Collagenase A (from Roche) in RPMI complete solution. The tissue was
digested for about 45 min in a 37*C water bath, vortexing at 15-20 min intervals. Then, digested
tissues were gently mashed between rough surfaces of two microscope slides immersed in RPMI
complete to release lymphocytes. Cell suspensions were filtered through an 80-ptm nylon mesh
(Sefar) and transferred into 15-ml Falcon tubes kept on ice.
To extract cells from the lungs, each specimen was ground through a cell strainer in 10
ml of RPMI complete. Then the suspension was centrifuged and resuspended in 2 ml of 2 mg/ml
Collagenase A (from Roche) in RPMI complete solution. The tissue was digested for 1 hr in a
37*C water bath, vortexing at 15-20 min intervals. An equal volume of 70% Percoll was added to
the digest followed by centrifugation at ~2000 rpm for 20 min. Tissue debris and supernatant
from lungs were gently aspirated, followed by RBC lysis.
Red Blood Cell (RBC) Lysis: Two milliliters of red blood cell lysis buffer (144 mM ammonium
chloride and 17 mM Tris-HCl pH7.4 in distilled deionized water) was added to pellets from
spleen and lungs specimens and kept on ice for 2-4 min, vortexing at 2 min intervals. Ten
millimeters of RPMI complete was added to stop the lysis. Cell suspensions were centrifuged at
~1200 rpm, resuspended in an appropriate buffer for further analysis, and filtered through a
nylon mesh (Sefar) into appropriately labeled tubes kept on ice.
Cell Counting: The total number of viable cells for each tissue specimen was counted using a
hemacytometer and tryphan blue exclusion.
Flow Cytometry: Appropriate numbers of counted cells in suspension were transferred into
labeled Falcon@ round-bottom tubes (FACS tubes), and centrifuged at ~1200 rpm for 5 min. All
procedures were performed on ice. Antibodies in FACS buffer (1% BSA and 0.1% sodium azide
in lx PBS) were used for staining following the manufacturer's recommended range. Purified
anti-mouse CD16/32 (BioLegend), the Fc blocker, was added for 10 min prior to adding the
primary antibody. Cells were incubated with the primary biotinylated antibody on ice for 30-45
min, washed and then incubated with the secondary and fluorophore-conjugated antibodies for
15-20 min while covered with foil paper. The cells were washed again, and resuspended in 50-pl
of DAPI or 1 [tg/ml propidium iodide solution except where indicated. Samples were sorted
using a BDTM LSRII or BD FACSCaliburTM flow cytometer (BD Biosciences). Further data
analysis was carried out using FlowJo software (Tree Star, Inc., Ashland, OR).
StatisticalAnalyses: All p-values are from unpaired two-tailed equal variance Student's t-Tests.
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CHAPTER 2
MASS BALANCE ANALOGY APPROACH TO IDENTIFY FACTORS CONTRIBUTING
TO T CELL PERSISTENCE
2.1. Summary
This chapter explores various mechanisms by which T cells may be persisting in the
TRAMP-SLY prostate. First, we investigated the role that cell trafficking may have on the
persistence of T cells in the prostate. Depletion of cells from lymphoid tissues such as the spleen
and PDLN, and persistence of antigen-specific T cells in the prostate suggested that cells may be
trafficking from the other tissues into the prostate. Memory cell transfer experiments into donor
TRAMP and TRAMP-SIY indicated that 2C T cells do not preferentially migrate into the
TRAMP-SLY prostate. Other experiments evaluating cell migration markers such as CCR7 and
CD62L also did not show any appreciable difference between 2C T cells from TRAMP and
TRAMP-SIY mice. Our analysis of IL-7Ra expression indicated that deletion rather than cell
trafficking may explain the markedly reduced cell numbers in spleens and PDLN of SlY-
expressing mice. All these results strongly suggest that cell trafficking is not one of the main
mechanisms by which T cells persist in a tolerizing tumor environment.
Another mechanism that may contribute to T cell persistence is proliferation.
Accumulation of transferred memory 2C T cells preferentially in recipient naYve TRAMP-SIY
mice indicated that persistence may be due to T cell proliferation. A series of experiments which
include (1) dilution of CFSE in CFSE-labeled memory 2C T cells, (2) incorporation of BrdU in
persisting T cells and (3) identification of S-phase cells in freshly isolated 7-AAD labeled T cells
confirmed that this is the case. These results are in stark contrast to previous literature about
tolerant T cells but agree with reports about persisting 'exhausted' non-functional T cells in
chronic infection models. This chapter reveals that the main mechanism by which T cells persist
in the tolerizing tumor environment is through proliferation.
Also, we investigated the effect of changes in cell death or survival on T cell persistence.
Previous publications showed that tolerant T cells are more sensitive to death. We chose to
analyze markers that might suggest a change in tolerant T cell death. We analyzed expression of
Fas, Caspase-3, and Annexin V in the apoptosis cell death pathway. Only our RNA analysis of
Fas expression and intracellular staining for cleaved Caspase-3 indicate an increase in cell death
among tolerant T cells. No significant difference could be found in the analysis for Fas protein
expression or Annexin V/7-AAD staining of tolerant versus non-tolerant T cells. One of the
reasons for these mixed results may be the different timepoints of the analyses and poor
sensitivity of the assays. However, the lack of correlation between cell number trends and
proliferation patterns still makes us infer that tolerant T cells are more prone to death. Thus,
although tolerant T cells persist by proliferating extensively, it appears their persistence is
limited by their increased sensitivity to cell death.
2.2. Introduction
This phenomenon of cell persistence can be likened to the mass and material balance
problems solved in engineering systems. For a given system, there are input, output, and internal
processes that help to determine the overall state of the system. By defining our system of
interest as the prostate, we can identify the analogous input, output and internal processes that
might contribute to T cell persistence in the prostate. Cell trafficking and migration are input
and output processes that can alter the number of T cells one may observe in the prostate at any
given time. Within the prostate, cell proliferation and death could also be occurring. Figure 3 is
a schematic of this mass balance analogy. Using the TRAMP-SLY model, we have observed that
2C T cells persist in the prostate but are depleted from other tissues. Therefore, these T cells
may persist by (1) cell trafficking from other tissues into the prostate tumor environment, (2) cell
proliferation in the prostate, and/or (3) increased T cell survival or a decrease in the death rate of
T cells in the tolerizing environment. This chapter investigates the role of each of these factors
in persistence of tolerant T cells.
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Figure 3. Schematic of processes that may contribute to T cell persistence ("Mass Balance"
Analogy).
Image of prostate tissue is from Hurwitz A.A. et al. (2001)1.
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2.3. Role of Cell Trafficking in T Cell Persistence
2.3.1. Results
Depletion of T cells from the spleens is antigen-specific
Using flow cytometry, we analyzed the number of 2C T cells in B6 (non-tumor, non-
antigen) and B6-SIY (non-tumor) tissues, and recognized that depletion of antigen-specific 2C T
cells in B6-SIY spleens is similar to that seen in TRAMP-SIY spleens (Fig. 4). The total number
of CD8* T cells is similar in all mouse models (Fig. 5). These trends suggested an effect of
expression of SLY antigen in the prostate on depletion of antigen-specific T cells in the spleens.
To determine whether this depletion effect is antigen-specific, we adoptively transferred
CD8* T cells with another TCR, OT-I T cells, which would not recognize SLY antigen presented
on the MHC-I complex. Mice that received naYve OT-I T cells were also infected with low dose
WSN-SIINFEKL (abbreviated WSN-SIIN) virus so that the OT-I T cells would be activated in
vivo and would be able to infiltrate all tissues. Then, tissues from these mice were analyzed 2
mpi. OT-L T cells infiltrate and are maintained for at least 2 mpi in B6, B6-SIY, TRAMP and
TRAMP-SIY mice (Fig. 6). Interestingly, in the spleen, unlike the depletion pattern observed for
2C T cells (Fig. 4), B6-SIY and TRAMP-SIY mice maintain OT-I T cells in their spleens (Fig.
6). Again the total number of CD8' T cells is similar for all mouse models (Fig. 7). These data
suggests that the presence of SLY antigen in the prostate may be contributing to depletion of
antigen-specific 2C T cells from the spleens and other tissues.
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Figure 4. Tolerant antigen-specific T cells persist in the tumor environment but are
depleted from other tissues.
Prostates, lungs, spleens and PDLN from TRAMP-SIY (solid diamond), TRAMP (open
diamond), B6-SIY (solid triangle) and B6 (open triangle) mice were harvested nine days, one-
and two- months after 2C T cell transfer and WSN-SIY influenza infection as described in the
methods section. Cells were analyzed as described in Fig. 1. Each shape represents one mouse.
Solid black bars indicate the average of the data for each mouse model (n>5 per group). The p-
values for cell numbers from student t-tests comparing B6 to TRAMP, B6-SIY to TRAMP-SLY,
B6 to B6-SIY and TRAMP to TRAMP-SlY are given for p<0.05. Values p<0.01 are represented
with an asterisk (*) and p<0.05 are represented with a double asterisk (**).
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Figure 5. Total CD8' T cell numbers in 2C recipient mice.
Tissues from TRAMP-SIY (solid diamond), TRAMP (open diamond), B6-SIY (solid triangle)
and B6 (open triangle) mice were harvested at the times indicated after 2C T cell transfer and
WSN-SIY influenza infection as described in the methods section. Total numbers of CD8* T
cells were determined from flow cytometry analysis as previously described. Each shape
represents one mouse (n>5 per group). Solid black bars indicate the average of the data for each
mouse model. The p-values for cell numbers from student t-tests comparing B6 to TRAMP, B6-
SIY to TRAMP-SIY, B6 to B6-SIY and TRAMP to TRAMP-SLY are given for p<0.05. Values
p<0.01 are represented with an asterisk (*) and p<0.05 are represented with a double asterisk
(**).
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Figure 6. Non-antigen-specific OT-I T cells are not preferentially depleted from lymphoid
tissues of SIY-expressing mice.
Prostates, lungs, spleens and PDLN were harvested two-months after OT-I T cell transfer and
WSN-SIIN influenza infection from TRAMP-SlY (solid diamond), TRAMP (open diamond),
B6-SIY (solid triangle) and B6 (open triangle). Cells were stained with vc2, v35, and CD8a
antibodies, as well as PI to exclude dead cells, followed by flow cytometry analysis. After
gating on all live CD8' cells using the FlowJo software, OT-I cells were identified by gating on
va2* and v05+ cells. Total cell numbers were calculated by multiplying ratio of vcX2* v$5+ CD8'
cells from FlowJo analysis and the total cell numbers counted by hemacytometer and tryphan
blue exclusion before antibody staining. The cell number calculations and plot generation were
performed using Microsoft Excel. Each shape represents data for one mouse (n>5 per group).
Solid black bars indicate the average of the data for each mouse model. The p-values for cell
numbers from student t-tests comparing B6 to TRAMP, B6-SIY to TRAMP-SlY, B6 to B6-SIY
and TRAMP to TRAMP-SlY are given for p<0.05.
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Figure 7. Total CD8* T cell numbers in OT-I recipient mice.
Tissues from TRAMP-SlY (solid diamond), TRAMP (open diamond), B6-SLY (solid triangle)
and B6 (open triangle) mice were harvested at the times indicated after OT-I and WSN-SIIN
infection as described in the methods section. Total numbers of CD8* T cells were determined
from flow cytometry analysis as previously described. Each shape represents one mouse (n>5 per
group). Solid black bars indicate the average of the data for each mouse model. The p-values for
cell numbers from student t-tests comparing B6 to TRAMP, B6-SIY to TRAMP-SLY, B6 to B6-
SLY and TRAMP to TRAMP-SLY are given for p<0.05. Values p<0.01 are represented with an
asterisk (*) and p<0.05 are represented with a double asterisk (**).
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Depletion of T cells from the spleens correlates with low IL-7R a levels
Previous studies have shown that gradual loss of IL-1 5RD (CD 122) and IL-7Ra (CD 127)
in memory 2C T cells of WSN-SIY virus infected B6 mice corresponds to decline in 2C T cell
numbers in the lungs of these mice 2. 2C T cells in B6 spleens that maintain high levels of IL-
7Ra persist 2. Flow cytometry experiments were performed to determine the protein expression
levels IL-7Ra in 2C T cells from spleens of SlY-expressing and non-SIY mice. Analysis of IL-
7Ra expression in 2C T cells from the spleen revealed a correlation between IL-7Ra levels and
the presence of SIY antigen in the prostate (Fig. 8). As early as 1 mpi, 2C T cells from B6-SIY
and TRAMP-SIY spleens have lower levels of IL-7Ra expression compared to cells from B6
and TRAMP spleens. This difference remains evident at 2 mpi (Fig. 8). This lower level of IL-
7Ra correlates with depletion of 2C T cells from spleens of mice expressing SIY antigen in their
prostates.
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Figure 8. Depletion of antigen-specific T cells from the spleens correlates with low IL-7Ra
levels.
Spleens from TRAMP-SLY (red), TRAMP (blue), B6-SIY (orange) and B6 (green) mice were
harvested 2 months after 2C T cell transfer and WSN-SIY influenza infection. Cells were stained
with 1B2, CD8x, and IL-7RL antibodies, as well as PI to exclude dead cells. Using the FlowJo
software, IL-7Rao expression histograms were generated by gating on PINeg CD8' cells followed
by FSC versus SSC lymphocyte gating, selecting 1B2* CD8' cells, and finally, overlaying
histogram plots. Freshly isolated naive 2C T cells analyzed at the same time were used to
determine baseline level comparisons (gray shadow).
Cell trafficking does not seem to be a major contributor to T cell persistence
An additional explanation for the depletion observed in the spleens is that T cells may be
preferentially trafficking from other tissues into the TRAMP-SLY prostate where they persist. To
investigate the effect of cell trafficking from the spleens, we developed an adoptive transfer
system of memory 2C T cells. Previous work has shown that 2C T cells in the spleen are more
functional than cells from TRAMP-SIY prostate 3. We deduced that if cell trafficking is
occurring, then upon transfer of functional persisting 2C T cells into each mouse, one would
observe preferential entry of 2C T cells into TRAMP-SIY prostate. We generated functional
persisting memory 2C T cells in normal B6 mice. These B6 (Thyl.2) mice received naYve 2C
Thy1.1+ CD8' T cells and were infected with low-dose WSN-SIY influenza virus. After 1 mpi
when activated 2C T cells have transitioned into memory T cells 2, 2C Thy 1.1+ CD8' T cells
were isolated and magnetically sorted from the spleens. Further details about the procedure are
given in the methods section. Approximately 0.5 x 106 memory 2C Thyl .1+ CD8* T cells were
retroorbitally injected into TRAMP and TRAMP-SIY mice. None of the recipient mice have
ever been infected with WSN-SIY virus or previously received 2C T cells. Since TRAMP and
TRAMP-SIY mice are from a Thy1.2 background, this system allowed us to recognize the
presence of 2C T cells in any of the tissues by using Thy 1.1 and CD8a antibodies. After 36 hr
post-transfer (h36), the numbers of 2C T cells from different tissues were analyzed. The 2C T
cell numbers in the prostate, lungs, spleens, and PDLN are similar for both groups (Fig. 9). Each
mouse had approximately twenty 2C T cells in its prostate (Fig. 9). This h36 data suggests that
there are no differences in the ability of 2C T cells to migrate into the prostate of tumor
transgenic mice.
Further analyses of tissues from recipient mice kept at longer time points, nine, twenty
and sixty days after transfer, show that 2C T cells become tolerant (Fig. 10 and Table 1) and
accumulate (Fig. 9) in TRAMP-SlY prostate compared to TRAMP prostate. The 2C T cell
numbers in the spleens, PDLN and non-draining lymph nodes (NDLN) of TRAMP and TRAMP-
SLY mice are not statistically significantly different (Fig. 7). However, significantly lower
numbers of 2C T cells are found in the mesenteric lymph nodes (MesLN), another type of non-
draining LN, of TRAMP-SIY mice compared to TRAMP MesLN on day 60 (Fig. 7). Upon
analysis of the 2C T cells for PD-I expression, a marker to show the functional state of cells, the
cells accumulating in TRAMP-SLY prostate are predominantly PD-l high i.e. tolerant 2C T cells
(Fig. 10 and Table 1). When these memory 2C T cells are labeled with carboxyfluorescein
diacetate succinimidyl ester (CFSE) before transfer, the accumulation can be attributed to
extensive proliferation (Figs. 14 to 16) and not cell trafficking. Therefore, it appears that cell
trafficking is not one of the main mechanisms for T cell persistence in the tolerizing tumor
environment.
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Figure 9. Functional memory T cells become tolerant and preferentially accumulate in
TRAMP-SlY prostate. Memory 2C (Thyl.l) T cells were generated and sorted from B6
(Thyl.2) spleens as described in the methods section. After CD8* T cell enrichment, ~0.5 x 106
memory 2C Thy 1.1+ CD8' T cells were transferred into each TRAMP (open) and TRAMP-SIY
(solid) mouse by retroorbital injection. Tissues from recipient mice were analyzed for the
presence of Thyl.l+ and CD8* cells at different time points indicated after 2C T cell transfer.
MesLN stands for mesenteric lymph nodes and NDLN is a pooled sample of axial, brachial and
inguinal lymph nodes. Total cell numbers were calculated by multiplying ratio of Thy 1.1* CD8'
cells from FlowJo analysis and the total cell numbers counted by hemacytometer and tryphan
blue exclusion before antibody staining. Each point represents one mouse (n>3 per group). Solid
black bars indicate the average of the data for each mouse model. The p-values from student t-
tests comparing cell numbers from TRAMP to TRAMP-SLY are given for p<0.05.
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Figure 10. Functional memory T cells become tolerant in TRAMP-SlY prostate.
Memory 2C (Thy 1.1) T cells were generated in B6 (Thy1.2) mice, and 0.5 x 106 memory 2C
Thyl.1* CD8' T cells were transferred into TRAMP and TRAMP-SlY (as described in Fig. 9).
Cells from recipients were stained with PD-1 on 36 hr and day 20 after transfer to assess their
functional state. Using FlowJo software, histograms showing PD-1 expression were generated
and the percentage of Thy1.l+ CD8' cells that are PD- lhigh was determined. The gating was
determined using 2C T cells on day 0 (before transfer) and cells from the lung at d-20.
Table 1. Antigen-specific T cells accumulating in TRAMP-SIY prostate are tolerant.
Memory 2C (Thyl.l*) T cells were generated in B6 (Thyl.2) mice, and 0.5 x 106 memory 2C
Thy 1.1 + CD8* T cells were transferred into TRAMP and TRAMP-SLY (as described in Fig. 10).
Cells from recipients were stained with PD-I on day 20 after transfer to assess their functional
state. Using FlowJo software, histograms showing PD-I expression were generated and the
percentage of Thy I.l CD8* cells that are PD-lhigh was determined. The gating was determined
using 2C T cells on day 0 (before transfer) and cells from the lung at d-20. This table shows the
average and standard deviation values for two TRAMP and three TRAMP-SIY mice analyzed.
This experiment was performed twice.
TRAMP TRAMP-SIY % -value
Lun s 0.0 0.0 1.15 2.0 0.495
S leen 15.05 6.0 23.01 13.6 0.508
Prostate 30.75 + 1.2 79.67 4.6 0.001
PDLN 1.43 2.0 20.97 17.5 0.232
MesLN 37.88 46.7 35.19 27.3 0.938
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Figure 11. Similar CCR7 expression in TRAMP and TRAMP-SIY mice.
Tissues from TRAMP (red) and TRAMP-SlY (blue) mice were harvested 2 mpi and stained with
Thy 1.1 -APC, CD8a-FITC, and CCR7-PE antibodies, as well as PI for analysis by flow
cytometry. Note that CCR7 (eBioscience) was incubated at 37*C following optimized conditions
recommended by the manufacturer. FlowJo software was used to generate CCR7 histograms.
"Non-2C" histograms are CCR7 expression levels in Thy 1. 1 Neg CD8* T cells. This is a
representative plot of a pair of mice analyzed on the same day.
Lungs Prostate PDLN NDLN
TRAMP-SlY
TRAMP
Spleen
to, 10' 102 1 104 100 1o' 102 1o' 0,
FL2-H: CD02L-PE FL2-H: CD62L-PE
1o 10 tas 104 0o0 o, 02 00' 104
FL2-H:CD2L-PE FL2-H: CD62L-PE
1o 00s 102 00s t04
FL2-R: CD62L-PE
CD62L
Figure 12. Similar CD62L expression in TRAMP and TRAMP-SIY mice.
Tissues from TRAMP (red) and TRAMP-SIY (blue) mice were harvested 2 mpi and stained with
Thyl.1-APC, CD8a-FITC, and CD62L-PE antibodies, as well as PI for analysis by flow
cytometry. FlowJo software was used to generate CD62L histograms. "Non-2C" histograms are
CD62L expression levels in Thy 1. 1N CD8+ T cells. This is a representative plot of a pair of
mice analyzed on the same day.
Lungs
El
Prostate PDLN NDLN
*EJ TRAMP-SlY 2
OR TRAMP-SlY 1
R TRAMP
Prostate Spleen
101 102 103 10 4
FL2-H: CXCR4-PE
100 101 102 0 3 104
FL2-H: CXCR4-PE
CXCR4
Figure 13. TRAMP-SIY has similar or lower level of CXCR4 expression compared to
TRAMP tissues.
Tissues from TRAMP (red) and TRAMP-SlY (blue) mice were harvested 2 mpi and stained with
Thy 1.1 -APC, CD8ac-FITC, and CXCR4-PE antibodies, as well as PI for analysis by flow
cytometry. FlowJo software was used to generate CXCR4 histograms.
2.3.2. Discussion
One mechanism that could explain the depletion trend observed in spleens might be
preferential cell trafficking of antigen-specific 2C T cells from other tissues into the prostate and
retention in the prostate due to the presence of SIY antigen. Our results suggest that this is
probably not the case. Close examination of the 2C T cell numbers show that the decline in T
cell numbers in TRAMP-SIY spleen (~100 000 less than TRAMP spleen) is not reflective of the
number of cells increase in TRAMP-SIY prostate (-5 000 more than TRAMP prostate) (Fig. 4).
CCR7high T cells are reported to preferentially exit peripheral tissues while CCR71w T cells
accumulate in the tissue . CD62L has been shown to be necessary for migration of circulating
mature T cells into lymph nodes 5. Our analyses of CCR7 and CD62L expression do not indicate
any significant differences between 2C T cells from TRAMP and TRAMP-SIY tissues (Figs. 11
and 12). Also, 2C T cells from TRAMP-SIY tissues have similar or lower levels of CXCR4
compared to TRAMP (Fig. 13). Therefore, expression levels of these markers of cell migration
cannot explain the preferential depletion of 2C T cells observed in TRAMP-SIY spleens but not
in TRAMP spleens. Furthermore, because antigen-specific T cells are being depleted from other
tissues, it seems unlikely that they are leaving the prostate. Our use of a common approach of
transferring T cells from a donor to a recipient (Fig. 9) to evaluate cell trafficking indicated that
preferential proliferation in the presence of antigen rather than preferential cell trafficking
contribute to tolerant T cell persistence.
A more probable explanation for the depletion trend is an active process of deletion of
antigen-specific T cells from the spleen. The presence of persistent antigen in the prostate
creates a situation of persistent antigen-presentation, possibly by DC, in SIY antigen-expressing
spleens. As a result, 2C T cells are trapped in an "effector" T cell state. In accordance with this
state, 2C T cells from the spleens of SLY-expressing mice express low levels of IL-7Ra (Fig. 8).
Only mice that lack persistent antigen are able to progress to a memory phenotype of high IL-
7Rca levels (Fig. 6) needed for maintaining antigen-specific T cells in the spleen 2. Kaech et al.
(2003) showed that antigen-specific T cells with low IL-7Ra levels were more prone to
apoptosis 6. As a result, these cells did not persist 6. Our Annexin V and Caspase-3 cell death
assays have not been able to detect significant differences in apoptotic rates between 2C T cells
from TRAMP and TRAMP-SlY spleens (Figs. 20 and 21). However, it appears that depletion of
antigen-specific T cells from the spleen is correlated with low levels of IL-7Ra that could make
them more apoptotic. This deletion process contributes to the observation that tolerant antigen-
specific T cells preferentially persist locally in the tolerizing tumor and antigen transgenic
prostate.
2.4. Effect of Proliferation on T Cell Persistence
2.4.1. Results
Tolerant antigen-specific T cells proliferate extensively
To assess whether tolerant T cells could persist by proliferation, we adapted the memory
2C T cell transfer system. After T cell isolation and magnetic sorting, cells were labeled with
CFSE, and then transferred into TRAMP and TRAMP-SLY recipient mice (Figs. 14 to 16).
CFSE is a fluorescent dye that dilutes by one-half for every cell division that occurs. When the
cells are run through a fluorescence-based flow cytometer, multiple fluorescence intensity peaks
are observed. The number of cell divisions, and hence proliferation rate, can be determined from
the number of fluorescence intensity peaks present. We analyzed tissues from these recipient
mice on days 6 (Fig. 14), 9 (Fig. 15) and 20 (Fig. 16) after the cell transfer. By day 20, 2C T
cells in TRAMP-SlY prostate and PDLN appear to have completely diluted CFSE (Fig. 16),
whereas only about 40% of the 2C T cells in TRAMP prostate have undergone more than four
rounds of cell division (Fig. 16). This extensive cell division in TRAMP-SIY prostate is in
agreement with the >10-fold more 2C T cells in TRAMP-SLY prostate compared to TRAMP
prostate at day 20 post-transfer (Fig. 9) even though both mice received the same number of 2C
T cells initially. On day 9, about five-fold more 2C T cells from TRAMP-SIY spleen have
undergone more than four rounds of cell division compared to cells in TRAMP spleen (Fig. 15).
By day 20, there is no statistical difference in CFSE dilution in the spleens (Fig. 16). This
proliferation data based on CFSE dilution suggests that one of the mechanisms by which tolerant
2C T cells may be persisting in TRAMP-SLY prostate may be through extensive proliferation in
the presence of SLY antigen.
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Figure 14. Antigen-specific T cells become tolerant and proliferate in the presence of
antigen.
About 0.5 x 106 CFSE-labeled memory 2C Thy 1.1* CD8' T cells were transferred into TRAMP
and TRAMP-SlY mice by retroorbital injection. Details are given in the methods section. Six
days after transfer, tissues from recipient mice were stained with Thyl.1-APC and PD-i-PE
antibodies, as well as PI to exclude dead cells, and analyzed by flow cytometry. Each diagram is
data from pooling four mice per group. PD-i and CFSE histogram plots are shown for cells
gated on pINeg and Thyl.l+ lymphocytes. The numbers in the PD-i histograms indicate the
percentage of PD-i high cells determined using naYve 2C Thyl.I+ RAG-1- splenocytes as a
negative control. The numbers in the CFSE histograms are Thyl.l+ CD8* cells that have
undergone >4 rounds of CFSE dilution.
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Figure 15. T cells accumulate in TRAMP-SlY prostate because they are proliferating.
Memory 2C (Thy1.1*) T cells were generated and enriched for CD8* T cells by magnetic
negative selection. After enrichment, memory 2C (Thy 1. 1) T cells as described in the methods
section, were labeled with 5 jiM CFSE. About 0.5 x 106 memory 2C Thy1.1* CD8' T cells were
transferred into TRAMP and TRAMP-SIY mice by retroorbital injection. On day 9, tissues from
recipient mice were analyzed by flow cytometry. CFSE histogram plots are shown for cells
gated on pINeg, Thyl.1* and CD8* lymphocytes. The numbers in the histograms indicate the
percentage of Thyl.1* CD8* cells that have undergone >4 rounds of CFSE dilution. This is a
representative plot for two mice per group.
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Figure 16. Tolerant T cells proliferate extensively in the presence of antigen. Memory 2C
(Thy l.l) T cells were generated and enriched for CD8+ T cells by magnetic negative selection.
After enrichment, memory 2C (Thy1.1*) T cells as described in the methods section, were
labeled with 5 pM CFSE. About 0.5 x 106 memory 2C Thy1.l* CD8* T cells were transferred
into TRAMP and TRAMP-SIY mice by retroorbital injection. On day 20, tissues from recipient
mice were analyzed by flow cytometry. CFSE histogram plots are shown for cells gated on PI
negative, Thy1.1+ and CD8+ lymphocytes. The numbers in the histograms indicate the
percentage of Thyl.l+ CD8' cells that have undergone >4 rounds of CFSE dilution determined
using the FlowJo software proliferation algorithm on TRAMP prostate and applying it to other
tissues. The bar chart shows the average and standard deviation of all mice analyzed (n>6 per
group). The p-values p 0.05 from student t-tests comparing TRAMP to TRAMP-SIY are also
shown. Each experiment was performed at least thrice.
To determine the cellular turnover rate of persisting 2C T cells in TRAMP and TRAMP-
SlY mice, we also performed 5'-bromo-2'-deoxyruridine (BrdU) incorporation experiments.
This method has been used by several groups including Tough and Sprent (1994) to determine
the turnover of memory T cells 7,'. We reasoned that persisting T cells would have been formed
by 30 days post-infection (dpi). Therefore, mice received BrdU starting at 30 dpi. For short
pulse experiments, mice were injected intraperitoneally once with 2 mg BrdU and analyzed 36 hr
later i.e. 32 dpi. Alternatively, for longer pulse-chase experiments, TRAMP and TRAMP-SIY
mice received 0.8 mg/ml BrdU in drinking water for 16-days i.e. 46 dpi (Fig. 17), and then
resumed regular drinking water (without BrdU) for another two weeks (60 dpi). BrdU is a
thymidine analog incorporated into the DNA of proliferating cells and is detected by intracellular
staining using a BrdU antibody 7 . BrdU was administered in an opaque water bottle and the
water was changed daily because of reported BrdU sensitivity to light 7. At 32 dpi, 39 dpi, 46
dpi and 60 dpi, tissues from TRAMP and TRAMP-SIY mice were analyzed for 2C Thyl.1+
CD8* T cells that had incorporated BrdU. In agreement with the CFSE results, the proliferation
rate of 2C T cells from TRAMP and TRAMP-SIY spleens assessed by BrdU incorporation are
similar (Figs. 17 and 18). A short-term pulse (32 dpi analysis) did not show any significant
difference in BrdU incorporation for 2C T cells in the prostates of either mouse group (Fig. 18).
Using the benchmark from Tough and Sprent (2004) 7,8 tolerant TRAMP-SIY and non-tolerant
TRAMP 2C T cells in the prostate undergo rapid turnover (with 40 to 80% incorporating BrdU)
between 39 dpi to 60 dpi (Fig. 18). In the PDLN, TRAMP-SIY 2C T cells proliferate at
consistently higher levels than TRAMP 2C T cells (Fig. 18). This BrdU results from the PDLN
(Fig. 18) are in agreement with the analyses performed using CFSE-labeled cells transferred into
TRAMP-SIY recipients and processed on day-20 after the transfer (Fig. 16). These results
suggest that tolerant 2C T cells persist by extensive proliferation due to the presence of antigen
in the prostate.
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Figure 17. Persisting tolerant T cells incorporate BrdU.
TRAMP and TRAMP-SIY mice were infected and received 2C Thy1.1* cells as previously
described in other experiments. At 30 dpi, mice were either injected with 2 mg BrdU i.p. (from
BD Biosciences BrdU Flow kit) for analysis 36-hr later i.e. the 32 dpi data points. For longer
time points (46 and 60 dpi), mice received 0.8 mg/ml BrdU in drinking water that was changed
daily for 16-days. On the day of analyses, tissues from TRAMP and TRAMP-SlY mice were
processed and stained with Thy1.1-APC, CD8a-PE, and BrdU-FITC antibodies following the
manufacturer's protocol (BD Biosciences BrdU Flow kit Cat. #559619). Flow cytometry
analysis involved gating on CD8' lymphocytes followed by placing quadrants for Thy 1.1 versus
BrdU* cells. A 2C recipient TRAMP mouse that did not receive BrdU was also analyzed on the
day of staining as a negative control. The FACS plots shows an example of a FlowJo analysis at
46 dpi.
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Figure 18. Persisting tolerant T cells proliferate extensively in vivo.
TRAMP and TRAMP-SIY mice were infected and received 2C Thy 1.1+ cells as described in the
methods section. At 30 dpi, mice were either injected with 2 mg BrdU i.p. for analysis 36-hr
later i.e. the 32 dpi data points. For longer time points (39, 46 and 60 dpi), mice received 0.8
mg/ml BrdU in drinking water that was changed daily. On the day of analyses, tissues from
TRAMP and TRAMP-SIY mice were processed and stained with Thy1.1-APC, CD8aX-PE, and
BrdU-FITC antibodies for analysis by flow cytometry. The analysis involved gating on CD8'
lymphocytes followed by placing quadrants for Thyl.1 versus BrdU* cells. A 2C recipient
TRAMP mouse that did not receive BrdU was also analyzed on the day of staining as a negative
control. The percentage of Thyl.1* CD8' cells that are BrdU* was determined using the
equation % BrdU* 2C T cells = (BrdU* Thy1.1+ CD8* cells/ Total Thy1.1* CD8* cells) x 100%.
Each shape represents one mouse. Solid black bars indicate the average of the data for each
mouse model (n>4 per group). The p-values for cell numbers from student t-tests comparing
TRAMP to TRAMP-SlY p<0.05 are shown.
Spleen
3 -
2-
0
SFL3-: 7AAD-PrCP
120
90. 00
60-
30-
0 200 400 600 800 1000
FL3-H: 7AAD-PerCP
Prostate
80
67.6
20 
-
63.1
200-
0.78
M150 -
100 -
50-
0 200 400 600 800 1000
FL3-H 7AAD-PerCP
PDLN
1.5
05
0 200 400 600 800 1000
FL3-H: 7AAD.PerCP
30-
39.7
8.53
20- 6.4
10 -
-
10
0 200 400 600 800 1000
FL3-H: 7AAD-PerCP
39, 20 2-
4q63
10-1 1
5-
5 0.5
0 0 0
0 200 400 600 800 1000 0 200 400 600 800 1000 0 200 400 600 800 1000
FL3-H: 7AAD-PerCP FL3-H: 7AAD-PerCP FL3-H: 7AAD-PerCP
15 600-
) 42.2 36.7
m"- 15- 16,4
0 8730P-0 I
5 - 2005
0 .0 40 So000 10 0 200 400 600 S00 10000 20 400 600 000 1000 FL3-H: 7AAD-PerCP
600- 9
2.5- 47.8C )20.40.-
2 400- 0.49
-0.6
- 0.4 -
1 200
0.5 0.2
0 200 400 0 00 1000 0 200 400 600 00 1000 0 200 400 600 600 1000
FL3-H: 7AAD-PerCP FL3-H: 7AAD-PerCP FL3-H: 7AAD..PerCP
Figure 19. Tolerant T cells proliferate in situ.
TRAMP and TRAMP-SlY mice were infected and received 2C Thy 1.1+ cells as described in the
methods section. At 85 dpi, tissues from TRAMP and TRAMP-SlY mice were processed and
stained with Thyl.1-FITC and CD8a-APC antibodies followed by the protocol for 7-AAD
staining given in the BD Biosciences BrdU Flow kit. Details are given in the methods section.
The flow cytometry analysis involved gating on Thyl.1 + CD8* lymphocytes followed by
generating 7-AAD histograms. Gates for GO/G 1, S, and G2/M indicated in some histograms was
obtained by applying the Dean-Jett-Fox cell cycle model in the FlowJo software to each
histogram. The program would not generate gates for the others.
2.4.2. Discussion
Cell proliferation is one of the main mechanisms contributing to persistence of T cells in
the tolerizing TRAMP-SIY prostate. Analysis of CFSE-labeled T cells show that tolerant 2C T
cells proliferate extensively in the presence of antigen (Figs. 14 to 16). BrdU pulse-chase
experiments analyzing persisting 2C T cells in the prostate showed rapid turnover of both
tolerant and non-tolerant 2C T cells (Fig. 18). Staining of cells from the prostate and PDLN with
7-aminoactinomycin D (7-AAD) showed some tolerant T cells in the S and G2/M phase of the
cell cycle (Fig. 19). This data further supports the fact that tolerant T cells can persist by
proliferating in vivo. This is contrast to reports that tolerant T cells are characterized by impaired
proliferation. Local immunosuppression has been observed in human patients with esophageal
squamous cancer 9. Even when systemic immunity was preserved, only lymphocytes extracted
from the tumor-draining lymph nodes of esophageal squamous cancer patients exhibited
impaired proliferation and cytolytic function in vitro 9. However, lymphocytes from draining
lymph nodes of some patients with esophagogastric adenocarcinoma in the same report actually
showed increased proliferative capacity after stimulation with phytohemaglutinin (PHA)
compared to cells from the reference (non-draining) lymph nodes 9. The authors do not show
whether these extensively proliferating cells from a different form of cancer also had impaired
cytolytic function. Studies evaluating proliferation and cytolytic activity are often carried out in
vitro 9, 10 and may not accurately reflect tolerant T cell response to antigen in the tolerizing
environment in vivo. The use of a mouse model that tolerizes antigen-specific T cells locally in
the tumor environment has allowed use to investigate and reveal the proliferative ability of
tolerant T cells in vivo.
2.5. Effect of Change in Survival/Death Rate on T Cell Persistence
2.5.1. Results
One of the other reported characteristics of tolerant CD8' T cells is increased sensitivity
to cell death 14. To assess cell death by apoptosis, Annexin-V, Caspase-3 and Fas (CD95)
expression in 2C T cells were examined. The Annexin V assay showed no difference in the
percentages of apoptotic or dead cells in 2C T cells from TRAMP and TRAMP-SIY mice (Fig.
20). It is possible that this assay is not sensitive enough to detect slight differences in apoptotic
rates. As a result, I decided to investigate expression of upstream molecules, Caspase-3 and Fas,
in the apoptotic pathway. Intracellular staining for caspase-3 expression only showed a
borderline difference (p=0.05); TRAMP-SIY prostate had a higher percentage of Caspase-3* 2C
T cells than TRAMP prostate (Fig. 21). Fas is an upstream inductor of apoptosis which had been
identified as one of the differentially expressed genes in a PCR Superarray screen. The Fas
transcript levels were about 15-fold greater in 2C T cells from TRAMP-SIY compared to those
from TRAMP prostate 30 dpi (Fig. 22). Using flow cytometry, there is no difference in the
percentages of 2C T cells expressing Fas protein (Fig. 23) between TRAMP and TRAMP-SIY
mice.
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Figure 20. No significant difference in Annexin V/7-AAD expression between 2C T cells
from TRAMP and TRAMP-SIY.
Tissues from TRAMP and TRAMP-SlY mice 46 dpi were processed as previously described.
(See Methods section for details.) Cells were stained with Thy 1.1, CD8a, Annexin-V and 7-
AAD. Then the stained cells were analyzed by flow cytometry. The FlowJo analysis involved
gating on 2C Thyl.l CD8* cells, and then drawing quadrants for Annexin V versus 7-AAD
cells. TRAMP spleen samples that were not stained or singly stained with either Annexin-V or
7-AAD were used to determine uadrant gates. The percentage (average ± standard deviation)
of 2C T cells that are Annexin-V Os 7-AADNe8 cells (right lower quadrant) and Annexin-V's 7-
AAD'S (right upper quadrant) are given. Statistical values are from analysis of two TRAMP-
STY and three TRAMP mice.
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Figure 21. Borderline difference in Caspase-3 expression between 2C T cells from TRAMP
and TRAMP-SIY prostate.
Tissues from TRAMP and TRAMP-SLY mice 85 dpi were processed and stained for Caspase-3
expression as described in the Methods section. The FlowJo analysis involved gating on Thy 1.1+
CD8* cells, followed by FSC versus SSC gating to select lymphocytes, and finally plotting
Thyl.1 versus Caspase-3. Spleens and prostate samples that were not stained with Caspase-3
were used to determine Thy1.1 versus Caspase-3 gate shown. The percentage (average ±
standard deviation) of Thy1.l+ Capase-3* are given for n = 3 -5 mice per group. The p-value
from student t-tests comparing five TRAMP-SIY and four TRAMP prostates is p=0.05. P-values
for other tissues are >0.2.
3 %J ________
2 Fas NhIh2 Tnfrsf10b
t- %_ *
-2 -
Cmal
Figure 22. Fas is among the genes differentially expressed between 2C T cells from
TRAMP and TRAMP-SIY prostate.
Fas is among genes differentially expressed (> 10-fold) in 2C T cells sorted from TRAMP and
TRAMP-SIY prostates 30 dpi in a PCR superarray screen for genes involved in tolerance.
Results show relative RNA levels of TRAMP-SIY to the same gene in TRAMP. All were
normalized to internal controls given in the Superarray. Experiments were performed by Eileen
Higham and Ching-Hung Shen (Chen Lab).
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Figure 23. No difference in Fas protein expression between 2C T cells from TRAMP and
TRAMP-SIY.
Tissues from TRAMP and TRAMP-SlY mice 39 dpi were processed as previously described.
(See Methods section for details.) Cells were stained with Thyl.1, CD8a, and Fas (CD95)
antibodies, as well as PI to exclude dead cells. Flow cytometry analysis involved gating on pINeg
CD8' lymphocytes followed by placing quadrants for Thyl.1 versus Fas cells. Spleen samples
that were not stained with Fas were used to determine quadrant gates. The percentage (average ±
standard deviation) of 2C Thy1.1* CD8' T cells that are Fas* cells (right upper quadrant) are
given. Statistical values are from analysis of three TRAMP-SlY and four TRAMP mice.
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2.5.2. Discussion
Thus far, our cell death assays have not been sensitive enough to detect slight significant
differences in apoptotic rates between freshly isolated tolerant and non-tolerant T cells (Figs. 20,
21 and 23). Annexin V is a protein that binds to phosphatidyl serine. When cells are dying by
apoptosis, they invert their inner membranes, thereby exposing phosphatidyl serine. 7-AAD is a
nucleic acid dye that is taken up by dying and dead cells. Combining fluorescently labeled
Annexin V and 7-AAD staining, one can identify cells in the early stages of apoptosis which are
Annexin V positive and 7-AAD negative, and cells that are in the late stages of apoptosis or dead
via necrosis (Annexin V positive and 7-AAD positive). Our assay showed low percentages of
apoptotic cells but no statistically significant difference between tolerant cells from TRAMP-SLY
compared to non-tolerant cells from TRAMP prostate (Fig. 20). Caspase-3 is one the molecules
activated in the cell apoptosis cascade, upstream of the membrane inversion stage detected by
Annexin V. By identifying Caspase-3* cells, one might identify cells that are more prone to
apoptosis. This assay showed a borderline difference (Fig. 21) indicating that tolerant T cells
from the prostate are probably more apoptotic than non-tolerant TRAMP T cells. Fas is an
upstream inductor of apoptosis. T cells expressing Fas can engage other cells including other T
cells that have the Fas ligand (FasL) which leads to a cascade of pro-apoptotic events that result
in death by apoptosis of the Fas-expressing cell ". However, there was no difference in Fas
protein expression (Fig. 23) even though RNA expression levels had indicated about a 15-fold
difference (Fig. 22) that suggested that tolerant T cells are more susceptible to Fas-induced
apoptosis. The inconsistencies in results from the different cell death assays may be due to the
varying timepoints when the assays were performed, as well as the tissue's efficient means for
clearing apoptotic cells. Our assays are performed at specific timepoints that may not
correspond to the optimal period for detecting apoptotic cells. Apoptotic cells are cleared rapidly
from tissues within 24 hr 1. It is possible that macrophages responsible for engulfing apoptotic
cells are performing this process efficiently 12 and the current assays cannot be used to detect
slight differences in apoptotic cell numbers.
However, we can still deduce that tolerant T cells in the TRAMP-SIY model seem to
have an increased sensitivity to cell death in the presence of antigen. This conclusion is drawn
from observing that the proliferation trend (Figs. 16 and 18) does not correlate with the cell
number trends (Fig. 4). Figure 4 shows that the number of 2C T cells in the TRAMP-SIY PDLN
at 2 mpi are about three-fold less than that in TRAMP PDLN. Yet, both CFSE and BrdU
methods reveal extensive proliferation (Figs. 16 and 18) in TRAMP-SIY PDLN. This deduction
is in agreement with other reports about the characteristics of tolerant CD8* T cells 10 in the
presence of antigen. In the InsHA transgenic mouse model, Hernandez et al. (2001) showed that
tolerant Clone 4 CD8* T cells proliferate locally in the draining lymph nodes and are eventually
deleted without any apparent cell trafficking occurring 13. These results are similar to our
observations in the PDLN of the TRAMP-SIY transgenic mouse model. In chronic infection
models, fully exhausted T cells exposed to high antigen load are deleted 14 because they are more
sensitive to death. Antigen-specific T cells in the TRAMP-SIY model are continuously exposed
to SLY antigen 15 which would induce exhaustive proliferation and deletion. An increased
sensitivity to cell death in the presence of persistent antigen might therefore be able to explain
the perceived impaired proliferation reported about tolerant T cells. This is because tolerant T
cells that proliferate extensively, that is incorporate BrdU or 3H-thymidine (a common analog
used in vitro proliferation assay), could die off more quickly, thereby leaving behind a lower
proportion of BrdU* or 3H* tolerant T cells. Our results suggest that persistence of tolerant T
cells is driven by extensive proliferation but it is also limited by increased sensitivity of tolerant
T cells to cell death in the presence of persistent antigen.
2.6. Materials and Methods
Mice & Viruses: 2C TCR and OT-I TCR transgenic mice on RAG1-/ and B6 backgrounds were
maintained at the Massachusetts Institute of Technology (MIT) Animal Care Facility. Congenic
2C TCR Thyl.1 mice were also bred in our facility. OT-I TCR CD45.1 transgenic mice on a
RAG2-1 background were a kind donation from Tyler Jacks lab at MIT. Recipient mouse strains
(TRAMP, TRAMP-SIY, B6 and B6-SIY), ages 3-8 months old, were also maintained in the MIT
facility. In some cases, B6 (C57BL/6) mice were purchased from the Jackson Laboratory (Bar
Harbor, ME). Recombinant WSN (HlN1) influenza virus with SIYRYYGL peptide engineered
onto the neuraminidase stalk originally constructed by plasmid-based reverse genetics 16 was
grown on Madine-Darby Canine Kidney (MDCK) cells. Similar methods were used to produce
WSN virus engineered with SIINFEKL (OVA) peptide sequence.
Antibodies & Reagents: Biotinylated 1B2 monoclonal antibody was produced in-house. 1B2 is
a monoclonal antibody specific for the 2C TCR. Other anti-mouse monoclonal antibodies,
CD16/32 (Fc blocker), Streptavidin-APC, CD8x-PerCP-Cy5.5 clone 53-6.7, CD8ax-APC,
CD8a-PE, CD8a-FITC, CD90.1(Thy1.1)-APC, CD90.1(Thy1.1)-FITC, v$5-FITC, va2-PE,
CD127(IL-7Ra)-FITC Clone A7R34, PD-1-PE clone J43, CD62L-PE, CCR7-PE,
CD184(CXCR4)-PE, Annexin-V-PE and CD95(Fas)-PE for flow cytometry studies were
purchased from BioLegend (San Diego, CA), BD Biosciences (San Jose, CA) or eBioscience
(San Diego, CA). 7-AAD was obtained from BD Biosciences BrdU Flow kit. Cleaved Caspase-
3 antibody (#9661) was purchased from Cell Signaling Technology (Danvers, MA) and the
secondary goat anti-rabbit IgG-PE antibody was obtained from Caltag. Pierce Chemical 4',6-
diamidino-2-phenylindole hydrochloride (DAPI) P146190 was purchased from VWR (USA).
Propidium iodide P4170 (PI) was purchased from Sigma-Aldrich (USA).
Lymphocyte Isolation (Lymph Nodes and Spleen): Lymph nodes (LN) and spleens from 2C
RAGl-i mice were extracted, one mouse at a time, after carbon dioxide (C0 2) inhalation. The
sacrificed animal's fur was sterilized with 70% ethanol. Dissected LN and spleens were stored
on ice in 4 ml of RPMI 1640 media supplemented with 5% fetal bovine serum and 10 mM
HEPES buffer solution (RPMI complete). After dissection, the LN were gently mashed between
rough surfaces of two microscope slides immersed in RPMI complete to release lymphocytes.
Cell suspensions were filtered through an 80-pm nylon mesh (Sefar) and transferred into 15-ml
BD Falcon tubes kept on ice. A similar procedure was followed for cell isolation from the spleen.
Splenocytes used for flow cytometry analysis were further purified by a red blood cell (RBC)
lysis step after grinding.
Cell Transfer & Influenza Infection: Cells isolated from 2C lymph nodes and spleens as
described above were resuspended in Hank's Balanced Salt Solution (HBSS, serum-free media),
filtered and kept on ice. Following approved animal care facility protocol, recipient mice were
anesthetized with 2.5% Avertin and intranasally infected with 100 pfu of WSN-SIY or 100 pfu
WSN-SIIN Influenza virus suspended in 50 pl. Still under anesthesia, infected mice were
immediately injected retroorbitally with 1-2 x 106 total live cells suspended in 100 p HBSS.
Memory Cell Transfer & Carboxyfluorescein Succinymidyl Ester (CFSE) Proliferation
Studies: B6 mice received 2C Thy 1.1 + T cells retroorbitally and were intranasally infected with
WSN-SIY virus as described above. One-month after infection, the spleens of these mice were
extracted and processed following the procedure above. The Miltenyi Biotec MACS CD8a' T
cell isolation kit (Cat. #130-090-859) was used to enrich for CD8' T cells. For the CFSE
proliferation studies, after enrichment, the cells were stained with 5 piM CFSE from Invitrogen
CellTraceTM CFSE cell proliferation kit (Cat. #C34554) following the manufacturer's
instructions. A portion of the enriched cell suspension (with or without CFSE) was analyzed by
flow cytometry to determine the number of 2C Thy 1.1+ CD8* T cells obtained after enrichment.
Then, the cells were resuspended in serum-free HBSS media such that each recipient mouse
received approximately 0.5x10 6 2C Thyl.l CD8' T cells in 100 pd of HBSS. Mice were
anesthetized with 2.5% Avertin before performing any retroorbital cell transfer injections.
Lymphocyte Extraction (Prostate and Lungs): Prostate lobes were extracted by microdissection
following procedures in Current Protocols in Immunology 1. Briefly, the urogenital system from
each mouse was extracted after CO2 inhalation, and transferred into 15-ml of RPMI complete on
ice. A dissecting microscope was used to identify prostate lobes in the urogenital system placed
on cold lx PBS. The prostate lobes were subsequently removed using tweezers and transferred
into 2-ml of 1 mg/ml Collagenase A (from Roche) in RPMI complete solution. The tissue was
digested for about 45 min in a 370C water bath, vortexing at 15-20 min intervals. Then, digested
tissues were gently mashed between rough surfaces of two microscope slides immersed in RPMI
complete to release lymphocytes. Cell suspensions were filtered through an 80-pm nylon mesh
(Sefar) and transferred into 15-ml Falcon tubes kept on ice.
To extract cells from the lungs, each specimen was ground through a cell strainer in 10
ml of RPMI complete. Then the suspension was centrifuged and resuspended in 2 ml of 2 mg/ml
Collagenase A (from Roche) in RPMI complete solution. The tissue was digested for 1 hr in a
37*C water bath, vortexing at 15-20 min intervals. An equal volume of 70% Percoll was added to
the digest followed by centrifugation at -2000 rpm for 20 min. Tissue debris and supernatant
from lungs were gently aspirated, followed by RBC lysis.
Red Blood Cell (RBC) Lysis: Two milliliters of red blood cell lysis buffer (144 mM ammonium
chloride and 17 mM Tris-HCl pH7.4 in distilled deionized water) was added to pellets from
spleen and lungs specimens and kept on ice for 2-4 min, vortexing at 2 min intervals. Ten
millimeters of RPML complete was added to stop the lysis. Cell suspensions were centrifuged at
~1200 rpm, resuspended in an appropriate buffer for further analysis, and filtered through a
nylon mesh (Sefar) into appropriately labeled tubes kept on ice.
Cell Counting: The total number of viable cells for each tissue specimen was counted using a
hemacytometer and tryphan blue exclusion.
Flow Cytometry: Appropriate numbers of counted cells in suspension were transferred into
labeled Falcon@ round-bottom tubes (FACS tubes), and centrifuged at ~1200 rpm for 5 min. All
procedures were performed on ice. Antibodies in FACS buffer (1% BSA and 0.1% sodium azide
in lx PBS) were used for staining following the manufacturer's recommended range. Purified
anti-mouse CD16/32 (BioLegend), the Fc blocker, was added for 10 min prior to adding the
primary antibody. Cells were incubated with the primary biotinylated antibody on ice for 30-45
min, washed and then incubated with the secondary and fluorophore-conjugated antibodies for
15-20 min while covered with foil paper. The cells were washed again, and resuspended in 50-
200 gl of DAPI or 1 tg/ml propidium iodide solution except where indicated. Note that cells
stained with CCR7-PE (from eBioscience) were incubated in a 37'C water bath following
optimized conditions recommended in the manufacturer's instructions. Samples were sorted
using a BDTM LSRII or BD FACSCaliburTM flow cytometer (BD Biosciences). Further data
analysis was carried out using FlowJo software (Tree Star, Inc., Ashland, OR).
Bromodeoxyuridine (BrdU) Proliferation: Mice received 2C T cells retroorbitally and were
intranasally infected with WSN-SIY virus as described above. Thirty days later, they were fed
0.8 mg/ml BrdU in their drinking water kept in opaque bottles. Their BrdU water was changed
daily for up to 16 days. Control mice received water without BrdU. BrdU administration was
stopped after 16 days (46 dpi), and regular drinking water was resumed for all mice. For short-
term pulse experiments, mice were injected intraperitoneally (i.p.) with 200 [1 of a 10 mg/ml
stock available from the BD Biosciences BrdU Flow kit (Cat. #559619). Therefore, each mouse
received one injection of 2 mg BrdU i.p. Tissues from these mice were analyzed 36 hr after the
injection. On the day of analyses, tissue harvest and processing procedures described above
were followed. 2C T cells that incorporated BrdU was determined by flow cytometry using the
BD Biosciences BrdU Flow kit (Cat. #559619). Antibody volumes suggested by the
manufacturer were adjusted to 100 pl for each sample (1:100 dilutions). Further data analysis
was carried out using FlowJo software and Microsoft Excel spreadsheet functions. The
percentage of 2C T cells that incorporated BrdU in each tissues (% BrdU+ 2C T cells) was
calculated as % BrdU+ 2C T cells = (BrdU* Thy1.l+ CD8' cells/ Total Thy1.l+ CD8* cells) x
100%.
7-aminoactinomycin D (7-AAD) Cell Cycle Analysis: Mice received 2C T cells retroorbitally
and were intranasally infected with WSN-SIY virus as described above. Eighty-five days later,
tissues from these mice were processed for extraction of lymphocytes as previously described.
These cells were stained with Thy L.1 -FITC and CD8a-APC antibodies, fixed and permeabilized
using the BD Biosciences BrdU Flow kit (Cat. #559619). The steps for BrdU staining were
omitted. Following the manufacturer's instructions, 100 pl of 7-AAD in BrdU kit staining buffer
was added to each sample (i.e. 20 pl 7-AAD and 80 pl buffer per sample). Further data analysis
was carried out using the Dean-Jett-Fox cell cycle model in the FlowJo software.
Caspase-3 intracellular staining: Freshly isolated cell suspensions were prepared as described
above. The procedure for Caspase-3 staining was performed following the instructions from the
manufacturer, Cell Signaling Technology which is briefly described here. Cells were stained
with Fc blocker, Thy 1.1 -APC and CD8a-FITC antibodies. Then the cells were fixed with 1 ml
of 3.7% of paraformaldehyde at 370C for 10 min, washed with Ix PBS and then permeabilized
with cold 90% methanol on ice for 30 min. Cells were washed with wash buffer (5g BSA in IL
of lx PBS) and then stained with Caspase-3 following recommended instructions by the
manufacturer. Controls did not receive Caspase-3. After incubation at room temperature (RT)
for 1 hr, cells were washed and stained with the secondary goat anti-rabbit IgG-PE antibody for
30 min at RT. Again the cells were washed and resuspended in wash buffer ready for analysis
by the BD FACSCaliburTM flow cytometer (BD Biosciences). Further data analysis was carried
out using FlowJo software (Tree Star, Inc., Ashland, OR).
StatisticalAnalyses: All p-values are from unpaired two-tailed equal variance Student's t-Tests.
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CHAPTER 3
THE EFFECT OF ANTIGEN IN T CELL PERSISTENCE
3.1. Summary
This chapter discusses the effect of antigen on T cell persistence. From the results
described in the previous chapters, one sees that antigen induces extensive proliferation of
antigen-specific T cells in vivo even when these cells are in a tolerizing environment.
Interestingly the presence of antigen also leads to depletion of antigen-specific T cells from
tissues with no or lower levels of antigen such as the spleen. This depletion correlates with low
levels of IL-7Ra. These combined effects lead to the perceived preferential persistence of
antigen-specific T cells in TRAMP-SIY prostate. Therefore, the presence of antigen is one of
the molecular factors contributing to T cell persistence in a tolerizing tumor environment.
3.2. Introduction
The fate of T cells after antigen encounter is variable depending on the amount of antigen
and the strength of costimulatory signal. The signal to T cells about the presence of foreign or
aberrant levels of self-antigen in the periphery is 'signal 1'. 'Signal 2' is the costimulatory
signals which usually involve B7 molecules signaling 1. In the presence of both signals, T cells
become activated. This activation process occurs in three phases in the draining lymph nodes
and takes about 48 hr with multiple transient and stable encounters with antigen-presenting cells
2 The activation process ends with proliferation i.e. clonal expansion of antigen-specific T cells
2 Activated CD8* T cells differentiate into effector T cells that can secrete cytokines, granule
proteins, and other molecules necessary for their continued expansion and lysis of target cells
presenting the antigenic peptide sequence on the appropriate MHC molecule. Typically, a T cell
contraction process follows. This contraction is a decline in antigen-specific T cell numbers due
to apoptosis. Persisting T cells after this contraction stage are called memory T cells and are
maintained by survival cytokines such as IL-7 and IL-15. Memory T cells can be restimulated
and expand in response to the same type of antigen initially used to generate them. This
narration above briefly describes the process that antigen plays in the generation of functional
persisting T cells.
In other cases, inappropriate amounts of antigen stimulation or costimulation leads to T
cell tolerance. There are three forms of tolerance in the periphery: (1) anergy, (2) deletion, and
(3) suppression by regulatory T cells 1, 3. Anergic T cells are those generated after antigen
stimulation and inadequate costimulation. These cells are unable to secrete IL-2 needed for
clonal expansion, and/or unable to perform their effector functions such as lysing target cells. In
the second form of peripheral tolerance, T cells experience repeated antigen stimulation, for
example, due to large doses of antigen, and are deleted due to apoptosis. This process is known
as activation-induced cell death (AICD), and may be Fas-mediated 1. The third type of
peripheral tolerance is induced by suppressive or regulatory T cells. In some cases, T cells that
have encountered antigen suppress the response of other T cells to the same antigen 1.
Published research has mostly focused on the role of antigen in the generation of tolerant
T cells but not on its role in maintenance of tolerant T cells. Several groups, including ours,
have shown that CD8' T cells infiltrate tumor sites. The fate of these T cells range from being
functional i.e. able to eradicate tumors, to the different forms of peripheral tolerance described.
T cells in the TRAMP-SIY prostate appear to be anergic and persisting. This chapter discusses
the role of antigen in the persistence of antigen-specific tolerant T cells.
3.3. Discussion
The effect of antigen on T cells is usually activation which leads to proliferation,
differentiation, anergy and/or apoptosis 1. Analysis of CFSE-labeled T cells show that tolerant
2C T cells proliferate extensively in the presence of antigen (Figs. 14 to 16). BrdU pulse-chase
experiments analyzing persisting 2C T cells in the prostate showed rapid turnover of both
tolerant and non-tolerant 2C T cells (Fig. 18).
Functionally impaired persistent T cells are also observed in chronic infection cases 4', 5
and studies in cancer models could aid understanding of what is occurring in chronic infections,
and vice-versa. In both cancer and chronic infections, antigen that can be processed and
presented to CD8* T cells, is always present in the tissue. Yet, antigen-specific CD8' T cells
become ineffective against tumor cells and chronic virus-infected cells, but persist in the tissue 4-
7. Recent reports show that some antigen-specific CD8' memory T cells are dependent on
antigen for their persistence 8-10. For example, Tanchot et al. (1997) showed that in the presence
of antigen and the correctly matched MHC class I molecules, memory CD8* T cells proliferate
and survive better than experimental groups without antigen 8. More recently, in cell transfer
experiments similar to ours, Shin et al. (2007) reported that antigen-specific CD84 T cells in
chronic lymphocytic choriomeningitis virus (LCMV) infected mice persist as a result of
extensive proliferation in the presence of antigen 9. These persisting CD8' T cells were
previously reported to be 'exhausted' or non-functional 4. Like the persisting non-functional
antigen-specific T cells generated in response to chronic LCMV infection 9, persisting T cells in
the tolerizing tumor environment are maintained by extensive proliferation in the presence of
persistent antigen 9.
Another interesting aspect of the effect of antigen is its role in the depletion of antigen-
specific T cells from peripheral tissues such as the spleen (Figs. 4 and 5). In chronic infection
models, fully 'exhausted' T cells exposed to high antigen load are deleted " because they are
more sensitive to death. Antigen-specific T cells in the TRAMP-SIY model are likely to be
continuously exposed to SIY antigen because of the leakiness of the probasin promoter 12. The
presence of persistent antigen in the prostate creates a situation of persistent antigen-
presentation, possibly by dendritic cells, in SlY antigen-expressing spleens. As a result, 2C T
cells are trapped in an "effector" T cell state. In accordance with this state, 2C T cells from the
spleens of SlY-expressing mice express low levels of IL-7R (Fig. 8). Only mice that lack
persistent antigen are able to progress to a memory phenotype of high IL-7Ra levels (Fig. 8)
needed for maintaining antigen-specific T cells in the spleen 13. Kaech et al. (2003) showed that
antigen-specific T cells with low IL-7Rc levels were more prone to apoptosis 1. As a result,
these cells did not persist 1. An increased sensitivity to cell death in the presence of persistent
antigen might therefore be able to explain the perceived impaired proliferation reported about
tolerant T cells. It might also explain the deletion of cells seen in other tissues such as the
spleen. Then one might ask "how are cells still persisting in the prostate of SlY antigen
expressing mice?" The answer seems to lie in the effect of tumor-related factors that seem to be
modulating the cell death effects of antigen. (See the next chapter for more details.)
The results so far show that the presence of antigen (1) drives extensive proliferation of
tolerant T cells and (2) correlates with low levels of IL-7Ra in peripheral tissues which make
these antigen-specific T cells sensitive to apoptosis. Therefore, persistence of tolerant T cells is
driven by extensive proliferation but it is also limited by increased sensitivity of tolerant T cells
to cell death in the presence of persistent antigen.
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CHAPTER 4
THE ROLE OF TUMORIGENIC/TUMOR-RELATED FACTORS IN T CELL PERSISTENCE
4.1. Summary
Analyses of cell numbers per gram of prostate indicate that factors in the tumor
environment, other than SlY antigen, contribute to T cell persistence. These factors are currently
referred to as tumorigenic or tumor-related factors to reflect the fact that mice analyzed in this
study are in their hyperplastic to neoplastic stages of prostate tumor progression before palpable
visible tumors can be detected. This chapter shows that these tumor-related factors do not
include IL- 15 and IL-7 which are cytokines known to support functional memory T cells.
Further analysis is also performed to determine potential candidates supporting T cell
persistence. From published microarray data comparing genes expressed in B6 and TRAMP
prostates, I identified 12 potential candidates that may support T cell infiltration, proliferation
and/or survival. Ten candidates were selected from genes differentially expressed that belong to
cytokines, chemokines, growth factors, cadherins or integrins gene ontology classes. These
classes were chosen because in general (1) cytokines and growth factors are known to promote
cell proliferation, while (2) chemokines, cadherins, and integrins usually have roles in cell
migration. The remaining candidates, Survivin and Racgapl, are two genes reported to be
differentially expressed between B6 and TRAMP prostate microarray datasets from two different
research groups. Further investigation is required to validate expression of these potential
candidates and determine whether they have a role in supporting T cell persistence in TRAMP
and TRAMP-SlY prostates.
4.2. Introduction
CD8' T cells infiltrate inflamed tissue and tumors. The presence of CD8' T cells at the
tumor site is often correlated with regression or at least slow progression of tumors in both
animal cancer models and human patients 1-3. The previous chapters have shown that antigen-
specific T cells infiltrate and persist in the TRAMP and TRAMP-SIY transgenic prostate cancer
models. In addition to antigen, factors from the tumor environment seem to be contributing to T
cell persistence. This chapter seeks to explore the role of these tumorigenic/tumor-related factors
and to identify molecular candidates supporting persistence of T cells. Some of these candidates
could include soluble factors such as IL- 15 and IL-7.
Studies in naYve and memory CD8+ T cells show that cytokines such as IL-15, IL-7, IL-2
and their receptors are important for CD8+ T cells' survival and maintenance 4~9. These
cytokines belong to the common-y chain (yc) family of cytokines. They all signal through yc but
specificity of function is conferred by their unique receptor subunits. IL-15 deficient (IL-15 >)
and IL- 1 5Ra-/~ mice have substantially lower numbers of naYve and memory CD8' T cells
compared to wild-type (IL- 15+1+) mice 4-6, 10-13. Marcondes et al. (2007) showed that simian
immunodeficiency virus, (SIV)-specific CD8' T cells persisted for over 6 months in the brains
of monkeys which had significantly increased levels of IL-15 after SIV, a chronic virus infection
4. No IL-2 was detected in this virus-infected organ 14. IL-15 levels did not change at other
tissue sites, and lower levels of IL-15 corresponded to loss of SIV-specific T cells 14. In benign
prostatic hyperplasia (BPH) tissues from human patients, inflamed prostate epithelial and stroma
cells were shown to express IL-15 and IL-15Ra 15. This high IL-15 level correlated with
increased T cell numbers in the prostate ". The authors showed that T cells from BPH prostate
showed a dose-dependent proliferative response to IL-15 but they did not assess the function of
the T cells present " More recently however, in a different chronic infection model, Shin et al.
(2007) demonstrated that persisting non-functional LCMV-specific CD8* T cells do hot depend
on IL-7 and IL-15 for their maintenance 16. No one has revealed if tolerant T cells in a tumor
environment persist due to the presence of IL-15, IL-7 or neither cytokine. IL-15 is secreted in a
trans presentation model 17 that is both IL-15 and IL-i 5Rc are produced by the same cells 18. In
order for cells to respond to IL-15 signals, IL-15Ra forms a complex with IL-15R@ and ye
receptor subunits found on target cells 19. Therefore signaling through IL-15 is a cell contact-
mediated process which results in memory CD8* T cell proliferation and maintenance. Although
current studies show that administering exogenous IL-15/IL-1i5Ra with T cells during
immunotherapy enhances survival of T cells in the recipient 20, 21 and reverses tolerant T cells
into functional cells 22,23 the role of endogenous IL-15 on persistence of T cells in a tolerizing
tumor environment has not been clearly defined.
IL-7 and IL-7R contribute to T cell survival by inducing proliferation and preventing
apoptosis 6, 24,25. Naive CD8' T cells proliferate in response to IL-7 both in vitro and in vivo 6.
In IL-7R'~ mice, B-cell lymphoma(Bcl)-2 expression is impaired, and correlates with diminished
memory CD8' T cell numbers compared to IL-7R** mice 6. Bcl-2 is a member of the Bcl-2
family of apoptosis regulatory molecules, which is found at high levels in surviving T cells 26-28
Memory CD8' T cells are partially dependent on IL-7 for homeostatic proliferation 6. In our lab,
Dr. Ching-Hung Shen showed that loss of IL-7Ra and IL-15R expression in memory 2C T
cells generated in response to WSN-SIY influenza virus, correlated with rapid decline of
memory 2C T cells from the lung airways 29. However, memory 2C T cells were maintained in
these mice's spleens where IL-7Ra and IL-15R@ was still being expressed 29. Like IL-15, the
main source of IL-7 for T cell proliferation in vivo appears to be non-bone marrow-derived cells
6. Again, the role of IL-7 in persistence of tolerant 2C T cells is yet to be elucidated. In this
study, we investigate the effect of tumor-related factors, and identify the role that IL- 15 and IL-7
might play in supporting persistence of T cells in a tolerizing tumor environment.
4.3. Results
Tumor-related factors have a dominant effect on persistence of tolerant T cells
Factors in the prostate tumor environment, which we call tumorigenic or tumor-related
factors, appear to support infiltration and persistence of T cells. Antigen-specific T cells
infiltrate both SLY antigen-expressing and tumor transgenic prostates by 9 dpi (Fig. 4). As the
time after infection progresses, there begins to be only statistically significant differences in 2C
T cell numbers between non-tumor (B6/B6-SIY) and tumor (TRAMP/TRAMP-SIY) transgenic
mice (Fig. 4). Observing that the tumor transgenic prostates appeared larger than normal mice,
we analyzed the number of 2C T cells per gram of prostate to rule out the possibility that the
increased cell numbers was simply due to larger tissue mass. Measurements of the dry weight of
the urogenital system and the dry weight of prostates showed that all mouse models had prostates
that were about ten percent of the urogenital system (Fig. 24). The urogenital system in this case
consists of the drained bladder, seminal vesicles, urethra, ureters, ampullary glands and the
prostate. The weight of the prostate was therefore calculated as 10% of the weight of the
urogenital system excised. These results showed that tumor transgenic mice had prostates about
thrice the size of non-tumor mice (Fig. 25). The analysis of the number of 2C T cells per gram
of prostate revealed a significant effect from the presence of antigen in the prostate at early time
points (9 dpi) while tumorigenic factors had a more dominant role on 2C T cell persistence (Fig.
26).
The effect of tumor-related factors on T cell persistence is also evident in experiments
using non-antigen-specific OT-I T cells. Prostates from tumor and non-tumor mice that received
OT-I T cells and WSN-SIIN virus were analyzed 2 mpi. The analysis of OT-I CD8* T cell
numbers revealed statistically significant differences between B6 versus TRAMP and B6-SLY
versus TRAMP-SlY prostates (Fig. 6). A comparison of the number of cells per gram of prostate
again showed that the tumor environment contributes to higher 'numbers' of T cells (Fig. 27).
The PDLN also showed markedly higher numbers between corresponding tumor and non-tumor
mice for both 2C (Fig. 4) and OT-I recipients (Fig. 6). These results suggest that in addition to
antigen, there are tumor-related factors that play a dominant role in supporting persistence of T
cells. Some of these factors may include cytokines such as IL- 15 and IL-7 that are known to
support functional memory T cell maintenance. The role of these cytokines in tolerant T cell
persistence is still unknown.
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Figure 24. Reason for ten percent estimation of prostate weight based on the weight of the
urogenital system.
The urogenital system and prostates of B6 (white), B6-SIY (stripes), TRAMP (dots) and
TRAMP-SIY (gray) mice were measured immediately following tissue excision. None of these
mice have ever been infected or received 2C T cells. The error bars indicate standard deviations
for each group (n = 5 -7 per group).
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Figure 25. Tumor transgenic prostates are thrice the weight of non-tumor prostates.
Chart shows average weights of B6 (white), B6-SIY (stripes), TRAMP (dots) and TRAMP-SIY
(gray) prostates for mice ranging from 4-8 months old at the time of harvest. The error bars
indicate standard deviations for each group (n>25 per group).
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Figure 26. Tumor-related factors contribute to T cell persistence.
Prostates were harvested after 2C T cell transfer and WSN-SIY influenza infection as described
in the methods section. 2C T cell numbers were determined as previously described. The
number of cells per gram of prostate was calculated using the weight of each mouse's prostate
determined at the time of tissue harvest. Each shape represents data for one mouse (n>5 per
group). Solid black bars indicate the average of the data for each mouse model. The p-values for
cell numbers from student t-tests comparing B6 to TRAMP, B6-SIY to TRAMP-SIY, B6 to B6-
SLY and TRAMP to TRAMP-SLY are given for p<0.05. Values p<0.01 are represented with an
asterisk (*) and p<0.05 are represented with a double asterisk (**).
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Figure 27. Tumor-related factors have a dominant role in the persistence of T cells in the
prostate.
Prostates were harvested after OT-I T cell transfer and WSN-SIIN influenza infection as
described in the methods section. 2C and OT-I T cell numbers were determined as previously
described. The number of cells per gram of prostate was calculated using the weight of each
mouse's prostate determined at the time of tissue harvest. Each shape represents data for one
mouse (n>5 per group). Solid black bars indicate the average of the data for each mouse model.
The p-values for cell numbers from student t-tests comparing B6 to TRAMP, B6-SIY to
TRAMP-SlY, B6 to B6-SIY and TRAMP to TRAMP-SlY are given for p<0.05. Values p<0.01
are represented with an asterisk (*) and p<0.05 are represented with a double asterisk (**).
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IL-15R/i, IL-7R a, IL-2R a and ye are expressed at similar levels in 2C T cells from the prostate
Upon comparison of the expression of the receptor subunits required for response to IL-
15, IL-7 and IL-2, no significant differences are observed at the RNA (Fig. 28) or protein (Figs.
29 to 33) level between tolerant and non-tolerant 2C T cells in the prostate. These cytokines all
belong to the ye family of cytokines. Flow cytometry analysis show similar levels of ye
expression in tolerant and non-tolerant 2C T cells (Fig. 29). Functional memory 2C T cells from
WSN-SIY infected B6 mice are known to express IL-15RD and IL-7Ra and to persist in the
spleen, whereas 2C T cells in the lungs gradually lose these receptor subunits, which corresponds
to a decline in 2C T cell numbers in the lungs 29. Thus B6 spleen and lung specimens were used
as positive and negative controls respectively. At all time points analyzed, 9 dpi, 1 mpi, 2 mpi,
the IL-15RP and IL-7Ra expression levels for 2C T cells in the prostate do not differ
significantly for all mice strains (Figs. 30 and 31). IL-2 shares the D and y receptor subunits with
IL- 15. The two cytokines can exert their unique effects by the difference in their a receptor
subunit. The expression level for IL-2Ra was also tested. No significant difference was
observed at 2 mpi for IL-2Ra (Figs. 33). In the prostate, the protein expression levels of all the
mouse strains overlap, and are slightly lower than those in naive 2C T cells (Figs. 29 to 31, 33).
Analysis of RNA levels of these receptor subunits in 2C T cells sorted from 1 mpi prostates also
showed less than 2-fold difference between TRAMP and TRAMP-SIY prostates (Fig. 28). This
data is in agreement with the protein expression assessed by flow cytometry. These results
indicated that tolerant and non-tolerant 2C T cells do not show differences in their response to
IL- 15 or IL-7 at the receptor level.
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Figure 28. Antigen-specific 2C T cells express similar levels of IL-15Rs and IL-7RcL in SIY
and non-SIY mouse prostates.
Relative mRNA levels of receptor subunits expressed in 2C T cells sorted from TRAMP and
TRAMP-SlY prostates and lungs 30 dpi (1 mpi). Data was extracted from a PCR superarray
screen performed by Eileen Higham (Chen Lab).
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Figure 29. No significant difference in ye expression between 2C T cells in TRAMP-SIY and
other mouse strains.
Lungs, spleens and prostates were harvested from TRAMP-SlY (red), TRAMP (green), B6-SlY
(orange) and B6 (blue) mice at 9 days, 1 month and 2 months after 2C T cell transfer and WSN-
SLY influenza infection. Cells were stained with I B2, CD8ca, and ye antibodies, as well as DAPI
or PI to exclude dead cells, followed by flow cytometry analysis. Using FlowJo software,
histograms were generated by gating on pINeg CD8+ cells followed by FSC versus SSC
lymphocyte gating, selecting 1B2* CD8' cells, and finally, overlaying histogram plots of each
receptor subunit as shown for the different mouse strains. Freshly isolated naYve 2C T cells were
used to determine baseline level comparisons (gray shadow).
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Figure 30. No significant difference in IL-15Rp expression between 2C T cells in TRAMP-
SIY and other mouse strains.
Lungs, spleens and prostates were harvested from TRAMP-SlY (red), TRAMP (green), B6-SlY
(orange) and B6 (blue) mice at 9 days, 1 month and 2 months after 2C T cell transfer and WSN-
SIY influenza infection. Cells were stained with 1B2, CD8a, and IL-15R$ antibodies, as well as
DAPI or PI to exclude dead cells, followed by flow cytometry analysis. The FlowJo analysis is
similar to that described for Y. Freshly isolated naive 2C T cells were used to determine baseline
level comparisons (gray shadow).
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Figure 31. Difference in IL-7Ra expression between 2C T cells in STY and non-SIY spleens
but not in prostates and lungs.
Lungs, spleens and prostates were harvested from TRAMP-SIY (red), TRAMP (green), B6-SIY
(orange) and B6 (blue) mice at 9 days, 1 month and 2 months after 2C T cell transfer and WSN-
SIY influenza infection. Cells were stained with 1B2, CD8c, and IL-7Rx antibodies, as well as
DAPI or PI to exclude dead cells, followed by flow cytometry analysis. The FlowJo analysis is
similar to that described for ye. Freshly isolated naive 2C T cells were used to determine baseline
level comparisons (gray shadow).
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Figure 32. Similar levels of IL-7Rax in the PDLN.
PDLN from three TRAMP (green) and TRAMP-SIY (orange) mice 2 mpi were pooled and
stained with 1B2, CD8a, and IL-7Rc antibodies, as well as PI to exclude dead cells, followed by
flow cytometry analysis using FlowJo software. Lungs, spleens and prostates from a pair of
TRAMP (red) and TRAMP-SIY (blue) mice were also analyzed. IL-7Ra expression histograms
were generated by gating on pINeg CD8* cells followed by FSC versus SSC lymphocyte gating,
selecting lB2* CD8* cells, and finally, overlaying histogram plots.
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Figure 33. No significant difference in IL-2Ra expression between 2C T cells in TRAMP-
SIY and other mouse strains.
Lungs, spleens and prostates were harvested from TRAMP-SIY (red), TRAMP (green), B6-SIY
(orange) and B6 (blue) mice at 9 days, 1 month and 2 months after 2C T cell transfer and WSN-
SIY influenza infection. Cells were stained with 1B2, CD8a, and IL-2Rx antibodies, as well as
DAPI or PI to exclude dead cells, followed by flow cytometry analysis. The FlowJo analysis is
similar to that described for yc. Freshly isolated naYve 2C T cells were used to determine baseline
level comparisons (gray shadow).
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2C T cells from tumor transgenic prostates respond similarly to IL-15 or IL- 7 stimulation
The effects of these cytokines on 2C T cells may be in the cells' response to IL-15 and
IL-7. In Fig. 31, we observed that IL-7Ra expression in the prostate is lower compared to naYve
2C T cells regardless of the presence or absence of SlY antigen. These results made us consider
the possibility that 2C T cells in the prostate may be responding to IL-7 in vivo. Increased
intracellular staining for phosphorylated Stat5 (pStat5) would indicate that tolerant T cells can
respond to this cytokine. pStat5 experiments were carried out using freshly isolated 2C T cells
from TRAMP and TRAMP-SIY prostates. Some cells were also stimulated with either IL-7 or
IL-15 to determine whether tolerant 2C T cells could respond to these cytokines. Figures 34 to
36 show the results. Unstimulated 2C T cells freshly isolated from TRAMP-SIY 1-2 mpi (-47
dpi) have similar or lower levels of pStat5 expression compared to 2C T cells from TRAMP
prostates (Fig. 34). When 2C T cells from TRAMP-SlY prostate are stimulated with IL-7 (20
ng/ml) or IL-15 (40ng/ml) for 30 min at 37*C, there is a slight increase (shift to the right, Figs.
35 and 36) in pStat5 levels. However, this is only 1-2 fold rise compared to 6-fold increase in
naive 2C T cells stimulated with IL-7 (Fig. 35). No appreciable difference was observed in 2C T
cells from TRAMP prostate after short-term stimulation with either cytokine (Figs. 35 and 36).
These results suggest that 2C T cells from TRAMP-SLY prostate do not respond differently to
IL-7 or IL-15 compared to cells from TRAMP prostate. In fact, tolerant 2C T cells do not appear
to respond to either IL-7 or IL-15.
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Figure 34. Phosphorylated Stat5 levels in 2C T cells from TRAMP-SIY prostate are lower
or comparable to TRAMP prostate.
Prostates were harvested from TRAMP-SIY and TRAMP mice 1- 2 mpi (-47 dpi) after 2C T cell
transfer and WSN-SIY influenza infection. Cells were stained with 1B2 and CD8a antibodies,fixed, permeabilized and stained with pStat5 antibody following the manufacturer's protocol
(Cell Signaling Technology) for flow cytometry staining. Data was analyzed using FlowJo
software. Histograms were generated by gating on FSC versus SSC to select lymphocyte-sized
cells, gating on 1B2* CD8* cells, and finally overlaying histogram plots of pStat5 expression for
each mouse strain shown. "Unstim" is an abbreviation for unstimulated cells.
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Figure 35. Tolerant 2C T cells do not respond to IL-7.
Cells from TRAMP-SlY prostates -47 dpi were analyzed for pStat5 expression as described in
the methods section. Using the FlowJo software, histograms showing pStat5 expression were
generated by gating on FSC versus SSC to select lymphocyte-sized cells, followed by gating on
Thyl.l* CD8* cells, and finally overlaying histogram plots of pStat5 expression. Unstimulated
cells are in red and stimulated cells are shown in blue. pStat5 levels on freshly isolated naive 2C
T cells that respond to IL-7 stimulation (blue) are shown as a positive control.
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Figure 36. Tolerant 2C T cells do not respond to IL-15.
Cells from TRAMP-SlY prostates ~47 dpi were analyzed for pStat5 expression as described in
the methods section. Using the FlowJo software, histograms showing pStat5 expression were
generated by gating on FSC versus SSC to select lymphocyte-sized cells, followed by gating on
Thyl.1* CD8' cells, and finally overlaying histogram plots of pStat5 expression. Unstimulated
cells are in red and stimulated cells are shown in blue. pStat5 levels on freshly isolated naYve 2C
T cells that respond to IL- 15 stimulation (blue) are shown as a positive control.
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IL-15 and IL- 7 are not expressed at detectable levels in tumor transgenic prostates
Because the results above (Figs. 28 to 36) showed that there were no differences at the
receptor level for tolerant 2C T cells that might explain their persistence in TRAMP-SlY
prostate, we chose to investigate whether the difference lay in the availability of the cytokine in
the prostate. RNA levels of IL-15 and IL-7 in TRAMP and TRAMP-SIY prostates were
determined by real-time quantitative PCR (qPCR) experiments. Cell suspension from the bone
marrow of B6 mice was chosen as a positive control since these cytokines are found in
abundance in this tissue. Although IL-7 and IL-15 could be detected in the bone marrow of B6
mice, neither of these cytokines could be detected in the prostate (Figs. 37 and 38). GAPDH was
used as the housekeeping gene, which served as an additional control. Since the GAPDH
expression using the same cDNA for the prostates could be detected easily (Fig. 39), we
confirmed that IL-15 and IL-7 are not produced in TRAMP and TRAMP-SIY prostates.
Therefore, persistence of tolerant 2C T cells in the prostate does not depend on IL- 15 or IL-7.
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Figure 37. IL-15 is not detected in tumor transgenic prostates.
RNA was extracted from prostates of TRAMP-SLY and TRAMP mice and transcribed into
cDNA (as described in the Methods section). The transcript levels of IL-15 and GAPDH were
determined using quantitative real-time PCR. Transcripts from the bone marrow of B6 mice
were used as controls. IL-15 levels were normalized to GAPDH levels of the same tissue. The
chart shows relative expression levels of IL-15 in the different tissues indicated. Error bars
represent the standard deviation from duplicate (B6) or triplicate (TRAMP and TRAMP-SIY)
samples.
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Figure 38. IL-7 is not detected in tumor transgenic prostates.
RNA was extracted from prostates of TRAMP-SlY and TRAMP mice and transcribed into
cDNA (as described in the Methods section). The transcript levels of IL-7 and GAPDH were
determined using quantitative real-time PCR. Transcripts from the bone marrow of B6 mice
were used as controls. IL-7 levels were normalized to GAPDH levels of the same tissue. The
chart shows relative expression levels of IL-7 in the different tissues indicated. Error bars
represent the standard deviation from duplicate (B6) or triplicate (TRAMP and TRAMP-SIY)
samples.
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Figure 39. GAPDH cycle thresholds are similar for all tissues.
RNA was extracted from prostates of TRAMP-SIY and TRAMP mice and transcribed into
cDNA. IL-15, IL-7 and GAPDH transcripts were run on the AB17500 thermacycler as described
in the methods section. This chart shows the average of the cycle threshold (Ct) values obtained
for each sample. Each RT product for qPCR was set up in technical duplicates. Two B6, three
TRAMP and three TRAMP-SIY mice were analyzed. Error bars represent the standard deviation
from all replicates.
120
Potential candidates that support T cell persistence
Tumorigenic or tumor-related factors might enhance T cell infiltration and/or increase
cell proliferation in the tumor environment. This deduction stems from the fact that tumor
transgenic prostates have about 5-fold greater number of 2C or OT-I T cell infiltrates at 2 mpi
than non-tumor mice (Figs. 4 and 6). Also, the number of 2C T cells increases at 5 mpi (Fig. 4).
(It is important to note that the texture of the tissue at 5 mpi is denser than earlier timepoints
analyzed and resembles that of solid tumors.) To identify potential molecules that support T
cells in the prostate tumor environment, I mined through published microarray data. Two groups
performed microarray analyses comparing gene expression in normal B6 prostates to TRAMP
prostates 30, 31. Of their top candidates differentially expressed in early stages of prostate tumor
progression (4-6 months old mice), both groups identified Survivin (also known as Birc5) and
Racgap1 as genes upregulated in TRAMP prostate relative to normal B6 prostate.
Survivin belongs to the family of Inhibitor of Apoptosis (IAP) genes 32 and has been
shown to be expressed in human and TRAMP prostates 33. Krajewska et al. (2003) evaluated
tissue sections from TRAMP prostates by immunohistochemisty. The authors found 93% of the
transformed foci in TRAMP mice with prostatic intraepithelial neoplasia expressing elevated
levels of Survivin compared to 33% of normal controls . Also, 47% of the transformed tissue
examined from mice with prostate cancer was positively stained for Survivin. Normal controls
did not have any cancer foci 3. Similar results have been observed in immunostained tissue
sections from prostate cancer patients 33. This data also correlates well with published
microarray results 30, 31. Other groups have been able to generate CD8* T cell specific response
to Survivin antigen in a variety of human cancers including patients with prostate cancer .
Their results suggest Survivin could induce T cell infiltration into the prostate. Furthermore, this
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molecule is important for proliferation of peripheral CD8' T cells 36. Xing et al. (2004)
discovered that Survivin-deficient mice had fewer CD8' T cells in the spleens and lymph nodes
but similar numbers to wild-type in the thymus 36. Additional studies showed that Survivin-
deficient cells' proliferation was impaired 36. CD8' T cells transduced with retroviral vectors
expressing Survivin proliferated and survived longer than non-transduced controls 37
Combining Survivin with Bcl-xL (another anti-apoptotic molecule) provided an additive effect
that resulted in functional persisting CD8+ T cells that prevented tumor growth 37. These results
suggest that Survivin could contribute to T cell persistence by inducing T cell infiltration into the
prostate tumor environment, as well as enhancing T cell proliferation and survival.
Racgap1 is the Rac guanosine triphosphatase (GTPase) activating protein 1, also known
as the male germ cell Rac GTPase activating protein (MgcRacGAP). As a GTPase activating
protein (GAP), Racgap1 acts as a catalyst by binding to activated Rho GTPases and thereby
negatively regulates Rho-mediated signals 3. Racgapl is involved in cytokinesis 38 and
hematopoietic stem differentiation including CD8* T cell development in the thymus 39, amongst
other roles, for example, migration of endothelial cells 40. In general these roles involve cell
proliferation and cell migration; two processes that may lead to increased T cells in the TRAMP
prostate. It is still unclear whether Racgapl would play a role in supporting persistence of
adoptively transferred T cells even though it is among the genes differentially expressed between
B6 and TRAMP prostates.
Considering that the mechanism for T cell persistence might occur through enhanced
proliferation, increased survival and/or through cell trafficking, I postulated that other candidates
that support T cell persistence might include chemokines, cytokines, growth factors, cadherins
and integrins. With the aid of a postdoctoral fellow, Dr. Guangan Hu, we identified genes in
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these categories that are differentially expressed in normal B6 versus TRAMP prostates (using
the public access dataset from the microarray analysis performed by Haram et al. (2008) 31.
Genes function that are classified in the gene ontology for chemokines and cytokines or growth
factors or cadherins and integrins were selected. Expression profiles of these genes were
extracted from the GEO dataset (GSE10525). Differentially expressed genes between B6 and
TRAMP prostates were identified using a nonparametric Wilcoxon-Whitney test in MeV
program (http://www.tm4.org/mev.html) with a false discovery rate FDR (<0.05) control.
Diagrams of expression profiles of these genes are shown in Figs. 40 and 41. Table 2 is a
summary of ten potential candidates obtained from this analysis.
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Figure 40. Genes upregulated in TRAMP prostate.
Genes differentially expressed between B6 and TRAMP prostates from mining GEO dataset
(GSE10525) made available by Haram et al. (2008) 31 for genes classified as cytokines and
chemokines or (A) growth factors or (B) cadherins and integrins in their gene ontology function.
(Cxcll2 was the only visually different gene in cytokines and chemokines analysis.)
Differentially expressed genes between B6 and TRAMP prostates were identified using a
nonparametric Wilcoxon-Whitney test in MeV program (http://www.tm4.org/mev.html) with a
False Discovery Rate FDR (<0.05) control (by Dr. Guangan Hu in Chen Lab).
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Figure 41. Genes downregulated in TRAMP prostate.
Genes differentially expressed between B6 and TRAMP prostates from mining GEO dataset
(GSE10525) made available by Haram et al. (2008) 31 for genes classified as (A) cytokines and
chemokines (A) or (B) growth factors in their gene ontology function. (Results from cadherins
and integrins test did not appear different visually.) Differentially expressed genes between B6
and TRAMP prostates were identified using a nonparametric Wilcoxon-Whitney test in MeV
program (http://www.tm4.org/mev.html) with a False Discovery Rate FDR (<0.05) control (by
Dr. Guangan Hu in Chen Lab).
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Table 2. Summary of candidates from Microarray analysis. List of genes differentially
expressed between B6 and TRAMP prostates from mining GEO dataset (GSE10525) made
available by Haram et al. (2008) 31. These genes were selected from genes classified as
cytokines and chemokines or growth factors or cadherins and integrins in their gene ontology
function. Differentially expressed genes between B6 and TRAMP prostates were identified
using a nonparametric Wilcoxon-Whitney test in MeV program (http://www.tm4.org/mev.html)
with a False Discovery Rate FDR (<0.05) control (by Dr. Guangan Hu in Chen Lab). Details
about known receptors on T cells, function, primer and antibody (abbreviated Ab) availability
were found through further literature searches. "Y" stands for Yes and "N" means No. The
blank spaces are for molecules where no reports were found.
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Gene Tumor Receptor on Function Primer Receptor Ab Soluble NeutralizingLevel T cells Available Available Factor Ab
Cxcl12 Up CXCR4, cell migration (CXCR4) and cellCXCR7 proliferation (CXCR7)
Ptn Up None found cell proliferation (fibroblasts), neurites N Y
outgrowth, bone mineralization
Kiti Up CDII7 (c-Kit hematopoiesis, spermatogenesis Y Y Y Y
receptor)
inhibitor of Tgfbeta family proteins
Htral Up None found (Bmp4, Bmp2, Tgfbetal) involved in Y
embryonic development
Col6al Up None found stimulation of PBMC CD8 T cells by
collagen VI peptides
cell migration of lymphocytes,
Igfbp5 Up None found monocytes and fibroblasts via MAPK Y Y
(abstract)
Nisch Up None found inhibitor of alpha5betal dependent cellmigration
ltgb1 Up CD49a-d forms VLA1-4, leukocyte adhesion to Y (and CD29 Y (CD49b, (membrane,ECM (collagens, laminin, fibronectin) Ab) CD49d) not soluble)
Cmtm8 Down None found clearance of EGFR and cell apoptosis Y
Egf Down None found cell proliferation via EGFR signaling Y Y
From this list of ten genes, two candidates, Cxcii2 and Itgb 1 may be selected for further
investigation because these molecules seem capable of supporting T cell persistence in the
prostate through cell migration or enhanced proliferation mechanisms. Both of these genes have
known receptors that are expressed on T cells. Furthermore, primers for these genes Cxcl 12 and
ltgbl are readily available from commercial vendors to validate their expression in B6 and
TRAMP models by qPCR analysis. Also, there are commercially available antibodies to the
receptors on T cells. Having antibodies to these receptors make it feasible to determine any
differences in the protein expression levels among 2C T cells from tumor versus non-tumor
prostates.
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4.4. Discussion
The persistence of adoptively transferred non-specific OT-I T cells also persisting in the
prostate suggested that other tumor-related factors support T cell persistence (Fig. 6), and may
even have a more dominating role than the presence of antigen. The analysis of T cell numbers
per gram of prostate revealed that the difference in 2C and OT-I T cell numbers between non-
tumor (B6/B6-SIY) and tumor (TRAMP/TRAMP-SIY) transgenic prostates (Figs. 26 and 27) is
not a result of prostate-intrinsic factors since the number of cells per gram of tissue for each
mouse model is not similar.
More recently, in a polyoma virus model, Swanson et al. (2009) also demonstrated that
antigen-specific memory CD8* T cells are maintained through an early antigen-dependent
proliferation phase and a later antigen-independent survival phase 41. It is clear from the
differences between non-tumor and tumor transgenic prostates that other antigen-independent
tumor-related factors support T cell persistence particularly at later timepoints (Fig. 26). It
appears that the presence of persistent antigen supports increased cell death. However, in the
prostate, T cells may persist because there are tumor-related factors that counter this effect. The
presence of these tumor-related factors may also explain why antigen-specific T cells persist in
the tumor environment but are depleted from other tissues without tumor factors. The
oncoprotein SV40 T antigen transgene in the TRAMP and TRAMP-SIY models are driven by a
prostate-specific probasin promoter 42 which would concentrate the tumor effects largely to the
prostate tissue. Interestingly, the total number of CD8* T cells when analyzed per gram of
prostate tissue in 2C and OT-I recipient mice is generally similar for all the mouse models
irrespective of whether they are tumor transgenic and/or express the SlY antigen in their
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prostates (Figs. 26 and 27). These data suggest that the prostate has additional molecules
regulating the number of T cells that persist in this tissue.
The results of this study revealed that tolerant 2C T cells do not depend on IL- 15 and IL-
7 for persistence in vivo. RNA and flow cytometry analyses of the receptor subunit expression
(Figs. 28 to 33) showed that there were no differences in the response to these cytokines between
tolerant and non-tolerant 2C T cells in the prostate. Signaling response of IL-15, IL-7 and IL-2
occurs through the Janus kinase - Signal transducer and activator of transcription (JAK-STAT)
pathway 43, 44. Phosphorylation of Stat5 in this pathway is an indicator that T cells are
responding to stimulation by IL-15, IL-7 and IL-2 43, 44. IL-7Ra is downregulated in cells
responding to IL-7 stimulation whereas all other receptor subunits (IL-1 5RD and IL-2Rct) are
upregulated in cells responding to IL-15 and IL-2. Although the levels of IL-7Ra are low in
antigen-specific 2C T cells, short-term IL-7 stimulation of freshly isolated T cells showed that
there were no differences in pStat5 levels (Fig. 35). These results suggest that tolerant T cells
have a similar response to IL- 15 and IL-7 as non-tolerant 2C T cells in the prostate, and in fact,
tolerant 2C T cells do not respond to either cytokine. Moreover, qPCR analyses revealed that IL-
15 and IL-7 are not detected in the prostate of tumor transgenic mice (Figs. 37 and 38).
Therefore, 2C T cell persistence cannot be dependent on the presence of these soluble factors,
IL-15 and IL-7.
These results are in contrast to those observed in tissue specimens from human patients
with BPH . Inflamed prostate epithelial and stroma cells from tissue specimens of patients with
BPH were shown to express IL-15 and IL- 5Ra 15. The authors correlated high levels of IL-15
with increased T cell numbers in the prostate, and showed that T cells from BPH prostate
showed a dose-dependent proliferative response to IL-15 in vitro. However, they did not assess
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the function of the T cells present 15. Dr. Ailin Bai also showed that the number of 2C T cells
from TRAMP and TRAMP-SIY prostates increase when cultured for four days in IL-2, IL-15
and IL-7 in vitro 2. Results from IFN-y and TNF-a secretion assays showed that these 2C T
cells were becoming functional 23. Therefore, it is possible that in the presence of these
cytokines, antigen-specific T cells are not tolerant. The difference in the functional state of the T
cells might explain the contrast between my results and those reported by Handisurya et al.
(2001) 15. In this study, with short-term (30 min at 37*C) IL-15 or IL-7 stimulation, freshly
isolated tolerant 2C T cells did not show appreciable response to either cytokine (Figs. 35 and
36) suggesting that these cells do not depend on this cytokine in vivo. Furthermore, the results
indicate that a short-time of stimulation is not enough to break tolerance. RNA transcripts of IL-
15 and IL-7 cannot be detected in the prostate environment where we have tolerant antigen-
specific T cells (Figs. 37 and 38). Therefore, persisting tolerant 2C T cells would not correlate
with high IL-15 levels.
Decline in IL-7 is correlated with persistence of tolerant T cells. Recently, Di Carlo et al.
(2009) reported loss of IL-7 in neoplastic glands from prostate cancer patients 45. Samples from
prostate cancer patients expressed approximately 60-fold less IL-7 mRNA compared to normal
prostates 45. Di Carlo et al. (2009) correlated this loss with a decline in functional CD8' T cells
that could infiltrate tumors; the remaining CD8' T cells were not terminally differentiated into
effector cells and were confined to the stroma, outside the glandular epithelial tumor regions 45.
Therefore, it appears that this is an example of non-functional CD8' T cells that might be able to
persist without IL-7 in vivo. This is in agreement with results in this thesis that tolerant 2C T
cells persist in TRAMP-SIY prostate without IL-7.
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This lack of dependence on IL- 15 and IL-7 has been observed in persisting non-
functional antigen-specific T cells generated in response to chronic LCMV infection 16 In this
article, persisting "exhausted" or tolerant T cells which expressed low levels of IL-1 5R and IL-
7Ra were maintained by extensive proliferation in the presence of persistent antigen 16. The
presence of antigen may explain the only difference observed in IL-7Ra expression in the
spleens (Figs. 31 and 32), and has been discussed in the previous chapter (about the effect of
antigen in T cell persistence). Gene expression profile analysis showed that exhausted T cells in
the LCMV model expressed higher levels of Jak3, and lower levels of both Jakl and Stat5b
transcripts compared to functional memory cells 46. These gene expression differences would
suggest that there are signaling deficiencies occurring in tolerant T cells 46. Therefore, like the
persisting non-functional antigen-specific T cells generated in response to chronic LCMV
infection 16, persisting T cells in the tolerizing tumor environment appear to be independent of
IL- 15 and IL-7, and maintained by extensive proliferation in the presence of persistent antigen.
The availability of published microarray data comparing gene expression between B6 and
TRAMP prostates prompted me to identify potential candidates that support T cell persistence
from this dataset. I postulated that the effects on infiltration, proliferation and/or survival could
be modulated through cytokines, chemokines, growth factors, cadherins and integrins. From the
published microarray data, a total of 12 candidates were identified (Table 2 including Survivin
and Racgapl). Of this list, Cxcl12 and Itgb1 seem feasible to investigate further since they have
known receptors on T cells and have readily available commercial reagents. Real-time qPCR
and flow cytometry results would be expected to show increased RNA and protein expression
levels in TRAMP prostates compared to normal B6 prostates. Also, small molecule inhibitors to
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the soluble factors may be used to assess the effect of these soluble molecules to T cell
persistence.
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4.5. Materials and Methods
Mice & Viruses: 2C TCR and OT-I TCR transgenic mice on RAG l'~ and B6 backgrounds were
maintained at the Massachusetts Institute of Technology (MIT) Animal Care Facility. Congenic
2C TCR Thy 1.1 mice were also bred in our facility. OT-I TCR CD45.1 transgenic mice on a
RAG2-1- background were a kind donation from Tyler Jacks lab at MIT. Recipient mouse strains
(TRAMP, TRAMP-SIY, B6 and B6-SIY), ages 3-8 months old, were also maintained in the MIT
facility. In some cases, B6 (C57BL/6) mice were purchased from the Jackson Laboratory (Bar
Harbor, ME). Recombinant WSN (HINI) influenza virus with SIYRYYGL peptide engineered
onto the neuraminidase stalk originally constructed by plasmid-based reverse genetics 4 was
grown on Madine-Darby Canine Kidney (MDCK) cells. Similar methods were used to produce
WSN virus engineered with SIINFEKL (OVA) peptide sequence.
Antibodies & Reagents: Biotinylated 1B2 monoclonal antibody was produced in-house. 1B2 is
a monoclonal antibody specific for the 2C TCR. Other anti-mouse monoclonal antibodies,
CD16/32 (Fc blocker), Streptavidin-APC, CD8a-PerCP-Cy5.5 Clone 53-6.7, CD8c-APC,
CD8a-PE, CD8c-FITC, CD90.1(Thyl.1)-APC, CD90.1(Thyl.1)-FITC, vp5-FITC, va2-PE,
CD122(IL-2/15RD)-FITC Clone TM- 1, CD127(IL-7Rx)-FITC Clone A7R34, CD127(IL-7Ra)-
Alexa Fluor@ 488, CD25(IL-2Ra)-FITC Clone PC-61.5, and CD132(ye)-PE for flow cytometry
studies were purchased from either BioLegend (San Diego, CA) or BD Biosciences (San Jose,
CA). Phospho-Stat5 (Tyr694) antibody (Cat. #9351S) was purchased from Cell Signaling
Technology, the secondary goat anti-rabbit IgG-PE antibody came from Caltag, and the isotype
IgG1-PE (A85-1) control antibody was purchased from BD Biosciences. Pierce Chemical 4',6-
diamidino-2-phenylindole hydrochloride (DAPI) P146190 was purchased from VWR (USA).
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Propidium iodide P4170 (PI) was purchased from Sigma-Aldrich (USA). RNeasy Plus Mini
(Cat. #74134) and RNeasy Fibrous Tissue Mini (Cat. #74704) kits were from QIAGEN (USA).
Taqman@ Universal PCR master mix (Cat. #4364340), Taqman@ Reverse Transcription
reagents kit (Cat. #N8080234), as well as IL-15 (Cat. #M00689964_ml), IL-7 (Cat.
#Mm00434291-ml) and GAPDH (Cat. #Mm99999915_gl) primers were bought from Applied
Biosytems (Foster City, CA).
Lymphocyte Isolation (Lymph Nodes and Spleen): Lymph nodes (LN) and spleens from 2C
RAG-1 mice were extracted, one mouse at a time, after carbon dioxide (C0 2 ) inhalation. The
sacrificed animal's fur was sterilized with 70% ethanol. Dissected LN and spleens were stored
on ice in 4 ml of RPMI 1640 media supplemented with 5% fetal bovine serum and 10 mM
HEPES buffer solution (RPMI complete). After dissection, the LN were gently mashed between
rough surfaces of two microscope slides immersed in RPMI complete to release lymphocytes.
Cell suspensions were filtered through an 80-pm nylon mesh (Sefar) and transferred into 15-ml
BD Falcon tubes kept on ice. A similar procedure was followed for cell isolation from the spleen.
Splenocytes used for flow cytometry analysis were further purified by a red blood cell (RBC)
lysis step after grinding.
Cell Transfer & Influenza Infection: Cells isolated from 2C lymph nodes and spleens as
described above were resuspended in Hank's Balanced Salt Solution (HBSS, serum-free media),
filtered and kept on ice. Following approved animal care facility protocol, recipient mice were
anesthetized with 2.5% Avertin and intranasally infected with 100 pfu of WSN-SLY or 100 pfu
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WSN-SIIN Influenza virus suspended in 50 [1. Still under anesthesia, infected mice were
immediately injected retroorbitally with 1-2 x 106 total live cells suspended in 100 [d HBSS.
Lymphocyte Extraction (Prostate and Lungs): Prostate lobes were extracted by microdissection
following procedures in Current Protocols in Immunology 48. Briefly, the urogenital system from
each mouse was extracted after CO 2 inhalation, and transferred into 15-ml of RPMI complete on
ice. A dissecting microscope was used to identify prostate lobes in the urogenital system placed
on cold lx PBS. The prostate lobes were subsequently removed using tweezers and transferred
into 2-ml of 1 mg/ml Collagenase A (from Roche) in RPMI complete solution. The tissue was
digested for about 45 min in a 37*C water bath, vortexing at 15-20 min intervals. Then, digested
tissues were gently mashed between rough surfaces of two microscope slides immersed in RPMI
complete to release lymphocytes. Cell suspensions were filtered through an 80-pm nylon mesh
(Sefar) and transferred into 15-ml Falcon tubes kept on ice.
To extract cells from the lungs, each specimen was ground through a cell strainer in 10
ml of RPMI complete. Then the suspension was centrifuged and resuspended in 2 ml of 2 mg/ml
Collagenase A (from Roche) in RPMI complete solution. The tissue was digested for 1 hr in a
370C water bath, vortexing at 15-20 min intervals. An equal volume of 70% Percoll was added to
the digest followed by centrifugation at -2000 rpm for 20 min. Tissue debris and supernatant
from lungs were gently aspirated, followed by RBC lysis.
Estimation of Prostate Weight: To estimate the weight of the prostate, immediately following
extraction, the urogenital system was weighed before being placed inside media, and then the
prostate weight was estimated as 10% of the weight of the urogenital system excised. The
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urogenital system in this case consists of the drained bladder, seminal vesicles, urethra, ureters,
ampullary glands and the prostate. Ten percent was selected after performing experiments
measuring the dry weight of the urogenital system and the dry weight of prostates, and showing
that all mouse models had prostates that were about ten percent of the urogenital system (Fig.
24).
Red Blood Cell (RBC) Lysis: Two milliliters of red blood cell lysis buffer (144 mM ammonium
chloride and 17 mM Tris-HC pH7.4 in distilled deionized water) was added to pellets from
spleen and lungs specimens and kept on ice for 2-4 min, vortexing at 2 min intervals. Ten
millimeters of RPMI complete was added to stop the lysis. Cell suspensions were centrifuged at
~1200 rpm, resuspended in an appropriate buffer for further analysis, and filtered through a
nylon mesh (Sefar) into appropriately labeled tubes kept on ice.
Cell Counting: The total number of viable cells for each tissue specimen was counted using a
hemacytometer and tryphan blue exclusion.
Flow Cytometry: Appropriate numbers of counted cells in suspension were transferred into
labeled Falcon® round-bottom tubes (FACS tubes), and centrifuged at ~1200 rpm for 5 min. All
procedures were performed on ice. Antibodies in FACS buffer (1% BSA and 0.1% sodium azide
in lx PBS) were used for staining following the manufacturer's recommended range. Purified
anti-mouse CD16/32 (BioLegend), the Fc blocker, was added for 10 min prior to adding the
primary antibody. Cells were incubated with the primary biotinylated antibody on ice for 30-45
min, washed and then incubated with the secondary and fluorophore-conjugated antibodies for
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15-20 min while covered with foil paper. The cells were washed again, and resuspended in 50-
200 pl of DAPI or 1 pg/ml propidium iodide solution except where indicated. Samples were
sorted using a BDTM LSRII or BD FACSCaliburTM flow cytometer (BD Biosciences). Further
data analysis was carried out using FlowJo software (Tree Star, Inc., Ashland, OR).
pStat5 intracellular staining: Freshly isolated cell suspensions were prepared as described
above for prostate tissue samples. Cells were stained with Fc blocker, Thyl.1-APC (or
Biotinylated 1B2 followed by Streptavidin-APC) and CD8a-FITC antibodies. Then cells were
stimulated with IL-7 (20ng/ml) or IL-15 (40 ng/ml) prepared in prewarmed RPMI complete.
Unstimulated controls did not receive cytokine. All cells were incubated in a 37'C waterbath for
30 min. After stimulation, the cells were fixed with 1 ml of 0.37% of paraformaldehyde at 37*C
for 10 min, washed with Ix PBS and then permeabilized with cold 90% methanol on ice for 30
min. Cells were washed with pStat5 wash buffer (5g BSA in IL of lx PBS) and then stained
with pStat5 following recommended instructions by the manufacturer. After incubation at room
temperature (RT) for 30 min, cells were washed and stained with either the secondary goat anti-
rabbit IgG-PE or the isotype control antibody for 30 min at RT. Again the cells were washed
and resuspended in pStat5 wash buffer ready for analysis by the BD FACSCaliburTM flow
cytometer (BD Biosciences). Further data analysis was carried out using FlowJo software (Tree
Star, Inc., Ashland, OR).
RNA Extraction and quantitative real-time PCR (qPCR): Femurs from B6 mice were extracted
and the bone marrows were infused with phenol red free HBSS (from GIBCO) to remove cells.
Prostate and spleens were also harvested directly into 4ml of HBSS in petridishes. Then freshly
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opened slides were used to grind these samples. After grinding, cell suspensions were
transferred into appropriately labeled 15-ml Falcon tubes. The cells were centrifuged and
resuspended in 1-1.5 ml of Ix PBS in order to transfer them into 1.5 ml eppendorf tubes. All
subsequent procedures were carefully carried out to prevent any RNase contamination. RNA
extraction for the bone marrow and spleens were performed using the RNeasy Plus Mini kit
while that for the prostates were done using the RNeasy Fibrous Tissue Mini kit. Appropriate
volumes of P-mercaptoethanol (p-ME) RLT buffer was added to each sample. Then a 23G1
needle followed by mixing with a 28 1/2G needle were used to create finer cell suspensions. To
eliminate the bubbles generated in this process, cells were frozen at -70*C for about 30 min.
Then they were warmed in a 37C waterbath for about 2 min. Defrosted cell suspensions in p-
ME RLT buffer were transferred into QIAGEN QlAshredder columns. Remaining steps for
RNA extraction followed the protocol from the manufacturer's kit handbook. Final volumes of
extracted RNA were 50 p.l. A Nanodrop spectrophometer was used to determine the RNA
concentration of each sample. On the same day, reverse transcription (RT) reactions for each
sample were performed to convert RNA into cDNA (RT product). This step used the Taqman@
Reverse Transcription Reagents kit (from Applied Biosystems) following volumes and
Thermacycler settings recommended by the manufacturer. Samples were stored at -20*C until
the day of qPCR analysis. To prepare qPCR samples, the RT product was transferred into wells
of optical plates. Each well contained 100 ng (based on original RNA concentration) of the
sample. A cocktail of 1 pl of primer (IL-7 or IL-15 or GAPDH), DNase-RNase-free water, and
2x Taqman@ Universal PCR Master Mix was added to each well. Total volume of qPCR premix
was 20 1il. Each tissue sample was prepared in duplicates. The plate was sealed with optical
caps and centrifuged for about 3 min to remove any bubbles. Then the plate was incubated at
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504C for 2 min, 95*C for 10 min, 95*C for 15 sec repeated 40 times, and finally cooled to 60*C
for 1 min using an ABI 7500 real-time PCR system (Applied Biosytems, Foster City, CA).
Relative expression levels were calculated using Microsoft Excel.
StatisticalAnalyses: All p-values are from unpaired two-tailed equal variance Student's t-Tests.
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FURTHER DISCUSSION AND FUTURE DIRECTIONS
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5.1. Discussion
This thesis elucidates the mechanism for persistence of antigen-specific T cells in a
tolerizing tumor environment using a spontaneous prostate cancer model referred to as the
TRAMP-SIY model. The results described in previous chapters show that 2C T cells do not
depend on IL-7 or IL-15 for persistence in vivo. Rather, a combination of antigen and tumor-
related factors contribute to infiltration and persistence of T cells in the prostate tumor
environment. In fact, the presence of antigen in the prostate correlates with depletion of antigen-
specific cells from the spleens and draining lymph nodes, thereby, contributing to perceived
persistence of antigen-specific T cells in the tolerizing TRAMP-SIY tumor environment. An
additional effect of antigen is inducing extensive proliferation of antigen-specific T cells in
TRAMP-SIY prostate, as well as increasing the sensitivity of antigen-specific T cells to cell
death. However the effects of antigen appear to be dampened by the dominant effect of tumor-
related factors on T cell persistence.
Validating potential tumor-related factors
Twelve candidates were identified as potential molecules that support T cell infiltration,
proliferation and/or survival in the prostate of tumor transgenic mice. Ten of these molecules are
upregulated in TRAMP prostates, while two are downregulated compared to B6 prostates
analyzed by microarray 1 2. Six of these candidates are soluble factors while one of them is
membrane-bound (Table 2). Cxcll2 and Kitl have commercially available neutralizing
antibodies that may be used to determine whether these molecules have an effect on T cell
persistence. The presence or absence of other molecules without readily available neutralizing
antibodies or small molecule inhibitors may be verified using real-time qPCR. Primers are
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commercially available (from Applied Biosystems Taqman gene expression assays) for all these
candidates except Survivin. Similar to the analyses performed in previous chapters, one may
compare B6 to TRAMP as well as B6-SLY prostates to TRAMP-SLY to validate that the
differences in gene expression are really due to the effect of tumor. Comparison of B6 to B6-
SLY and TRAMP to TRAMP-SLY would also help to elucidate any effect the presence of antigen
has on expression of this molecule. While real-time qPCR could serve as a first screen, it may be
more informative to also analyze the protein expression levels of these candidates. The
correlation between gene and protein expression results may not always hold because of post-
transcriptional and post-translational modification of these molecules. As a result, protein
expression from candidates from the first qPCR screen should be evaluated by flow cytometry
and/or western blotting, where antibodies are available. Itgbl, also known as CD29, is one
example of these candidates that has a commercially available antibody.
Identifying the role of potential tumorigenic factors
Ultimately the goal is to determine the effect of these molecules on T cells in vivo. Some
of these molecules such as Cxcll2, Kitl, and Ltgbl have known receptors on T cells a 4. To
assess their role on T cell persistence, since antibodies to these receptors are available, flow
cytometry may be used to determine whether there are differences in receptor expression levels
between T cells from tumor and non-tumor prostates. Further investigation could also be carried
out by using siRNA to knockdown genes or using retroviral constructs to express genes in 2C or
OT- CD8' T cells. These genetically modified cells may be adoptively transferred into B6 and
TRAMP recipient mice as described in previous chapters of this thesis. By using either 2C or
OT- cells, one can monitor the T cell numbers in different tissues by flow cytometry to
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determine whether there are differences in T cell infiltration and persistence. In addition, mice
deficient in any of these genes that are upregulated may be crossed onto the TRAMP mouse to
generate TRAMP gene X-deficient mice. A set of experiments would be to transfer 2C or OT-I
cells into TRAMP and TRAMP gene X-deficient mice, and determine the difference in T cell
numbers, proliferation and survival/apoptotic death rate upon loss of this gene.
Monitoring the effect on tumor progression
Of particular importance is the effect any of these factors could have on tumor
progression. Experiments to assess the function of T cells infiltrating the prostate should also be
carried out. One can assess function by measuring IFN-y and TNF-a secretion. Also, the level
of PD-1 expression can also serve as a marker of tolerance because tolerant cells often express
high levels of PD-1. If loss of a gene results in persisting functional T cells, then one may
conclude that this tumorigenic or tumor-related factor induces tolerance and limits T cell
persistence (possibly by inducing cell death or preventing proliferation).
Persisting functional T cells can limit tumor progression or prevent tumor growth
altogether. However, we have not monitored the growth of prostate tumors in the TRAMP-SIY
model yet. Magnetic resonance imaging (MRI) is a useful imaging modality for distinguishing
soft tissues with different fluid (water) densities. The first proof that nuclear magnetic resonance
imaging could be applied in biology came from experiments published in 1971 that compared
cancerous tissue from rats to healthy tissue 5. The author noted that cancerous tissue had longer
relaxation times 5. Depending on the acquisition settings, MRI can be used to differentiate
between normal and prostate tissue with tumors since the texture and water content of these
tissues should differ. This imaging modality does not require sacrificing mice at the time of
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imaging. Therefore, one can acquire MRI images of the prostate from the same TRAMP and
TRAMP-SIY mice starting from post-puberty (with tumor) stages to development of palpable
prostate masses. Age-matched normal B6 mice may be used as controls. There are two
constants in the magnetization equations, TI and T2, that describe the property of the tissue
being imaged 5,6. An image is described as Ti-weighted or Ti-dependent if its relative signal
intensity is highly dependent on the TI value of the tissue 5. Similarly, the image is called T2-
weighted or T2-dependent when it is sensitive to the tissue's T2 value 5. The MRI scanner can
be set to produce T1- or T2-weighted images by adjusting the pulse sequence of the magnetic
field 5. The result is that in TI images, fluid and air appear black, and are indistinguishable from
one another, whereas in T2 images, the brightest signal comes from fluid-filled areas 5 such as
the bladder. By quantifying signal intensity, one would be able to correlate changes in tissue
signal to development of tumor. These studies using mice that have not received 2C T cells
would help to establish baseline tumor progression in the tumor transgenic mouse models.
The effect of an identified tumorigenic factor on tumor progression may also be
evaluated through MRI studies. TRAMP gene-X deficient mice may be compared to TRAMP
mice. Also, mice that have received genetically modified 2C T cells may also be compared to
those controls without them. Tissue samples from these mice may also be analyzed by
immunohistochemistry to validate MRI results. By immunohistochemistry, one can determine
the neoplastic stages of the mouse and the extent of T cell infiltration into the prostate tissue. An
example of the use of MRI to monitor effectiveness of T cell immunotherapy was recently
published by Lazovic et al. (2008) 7. The authors used an orthotopic xenograft murine model to
demonstrate that genetically engineered glioblastoma-specific IL-13Rx2 T cells are effective in
lysing glioblastoma cells. Interestingly in their studies, by quantifying signal intensity of T2-
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and TI-weighted images, they showed that (1) T2 relaxation times, correlated with water content
in tumor and tumor edema, increased within 24-hr after T cell transfer, (2) a corresponding
enhancement occurred in Ti-weighted postcontrast images after 24-hr, (3) apparent diffusion
coefficient (ADC) levels, a measure of the diffusivity of water molecules, increased 2-3 days
after treatment, and (4) T 1-weighted postcontrast signal intensity decreased in glioblastoma sites
that received IL-13Ra2 T cells 3-days after cell transfer, although ADC levels remained elevated
7. The loss of this TI signal corresponded to significantly decreased tumor volume and
glioblastoma cell lysis evaluated by MRI and immunohistochemistry respectively, compared to
non-treated and nonspecific T cells recipient mice 7. This article demonstrates the potential use
of MRI to monitor early stages of T cell immunotherapy. Applying these techniques to studies
with the TRAMP-SIY model might help to evaluate therapeutic use of the novel candidates
identified.
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